{
  "users": [
    {
      "id": 1,
      "username": "Oliver",
      "password": "$pbkdf2-sha256$29000$qRUiROi911pr7T0HIMT43w$0wND3o7eOdfzDaHdpj0wDPDJJYyFwOYNgIarUiIRhys",
      "system_prompt": "please provide a 1:1 re-creation of the DETAILED INFORMATION based on the infos in the CONSOLIDATED PRODUCT OVERVIEW. Update the launch dates where appropriate - rules:\n* if products are marked as discontinued, this info is superior, launch date should be provided as \"(was: <year>)\"\n* ignore the missing profiles\n\n\nCONSOLIDATED PRODUCT OVERVIEW\n\n### **Consolidated Product Overview**\n\n| **Product Name / Number**           | **Label**     | **Modality Name**                                   | **Short Description**                                                                 | **Expected Launch Date** |\n|------------------------------------|---------------|-----------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------|\n| CT\u2011155 (BI 3972080)                | DTx (SaMD)    | Prescription Digital Therapeutic (SaMD/PDT)         | Smartphone-based PDT delivering psychosocial interventions for negative symptoms       | June 2026                |\n| CT\u2011156 (BI 4018711)                | DTx (SaMD)    | Prescription Digital Therapeutic (SaMD/PDT)         | Digital therapeutic targeting functional impairment in schizophrenia                   | 2028                     |\n| BI 3797479                         | NCE (solid)   | Small Molecule                                      | COMT inhibitor modulating dopamine metabolism for CIAS                                 | 2033                      |\n| BI 3798489                         | NCE (liquid)  | Peptides                                            | NMUR2 agonist peptide targeting satiety circuits for weight loss                       | Post-2035                |\n| BI 3812465                         | NBE           | Recombinant Proteins                                | Bispecific agonist mimicking Norrin to restore BRB in CI-DME                           | 2032                      |\n| BI 3814916                         | NBE           | Monoclonal Antibody                                 | TLR4 inhibitory mAb reducing hepatic/systemic inflammation in MASH                     | 2034                      |\n| BI 3819026                         | NBE           | Monoclonal Antibody                                 | Afucosylated IgG1 targeting LAYN to deplete tumor-resident Tregs                       | 2026                     |\n| BI 3820768                         | NBE (ntm)     | T-cell Engager                                      | Bispecific engaging ALPG and CD3 to activate T-cells in solid tumors                   | 2031                     |\n| BI 3821001                         | NBE           | Recombinant Proteins                                | Fc-fusion decoy receptor blocking TL1A and LIGHT in IBD                                 | 2035                      |\n| BI 3822971                         | NBE (ntm)     | T-cell Engager                                      | Bispecific antibody targeting LY6K-HLA and CD3 for tumor-specific cytotoxicity         | 2034                      |\n| BI 3940749                         | NCE (solid)   | PROTAC                                              | KRASmulti degrader recruiting CRBN E3 ligase for KRAS degradation                      | 2031                     |\n| BI 3968621                         | NCE (solid)   | PROTAC                                              | HPK1 degrader enhancing immune activation in solid tumors                               | 2035                      |\n| Spesolimab                         | NBE           | Monoclonal Antibody                                 | Anti-IL36R mAb blocking IL-36 signaling for PG and other neutrophilic dermatoses       | 2027                     |\n| Tenecteplase (TPA\u201103 / TPA\u201107)     | NBE           | Recombinant Proteins                                | Genetically modified rt-PA with enhanced fibrin specificity for AIS                     | 2029                     |\n| Zongertinib (BI 1810631)          | NCE (solid)   | Small Molecule                                      | Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI)                           | 2025                     |\n| Nerandomilast (BI 1015550)        | NCE (solid)   | Small Molecule                                      | Oral, preferential inhibitor of phosphodiesterase 4B (PDE4B)                            | 2025                     |\n| Survodutide (BI 456906)           | NCE (liquid)  | Peptides                                            | GCGR and GLP-1 receptor dual agonist                                                   | 2027                     |\n| Vicadrostat (BI 690517)           | NCE (solid)   | Small Molecule                                      | Aldosterone synthase inhibitor (ASi)                                                   | 2028                     |\n| Avenciguat (BI 685509)            | NCE (solid)   | Small Molecule                                      | Soluble guanylate cyclase (sGC) activator                                              | 2028                     |\n| BI 1569912                         | NCE (solid)   | Small Molecule                                      | NMDA subunit 2b-selective NR2B NAM                                                     | 2028                     |\n| BI 1358894                         | NCE (solid)   | Small Molecule                                      | TRPC4/5 inhibitor                                                                      | 2029                     |\n| BI 1291583                         | NCE (solid)   | Small Molecule                                      | Cathepsin C (CatC) inhibitor                                                           | 2029                     |\n| BI 1819479                         | NCE (solid)   | Small Molecule                                      | Autotaxin (ATX) inhibitor                                                              | 2030                     |\n| BI 706321                          | NCE (solid)   | Small Molecule                                      | RIPK2 inhibitor                                                                        | 2032                     |\n| BI 3032950                         | NBE           | Monoclonal Antibody                                 | TREM-1 antagonist                                                                      | 2033                     |\n| BI 764198                          | NCE (solid)   | Small Molecule                                      | TRPC6 inhibitor                                                                        | 2030                     |\n| BI 765845                          | NBE           | Recombinant Proteins                                | MYDGF (Heart disease modulator)                                                        | 2030                     |\n| BI 770371                          | NBE           | Monoclonal Antibody                                 | SIRP\u03b1 antagonist                                                                       | 2031                     |\n| BI 764524                          | NBE           | Monoclonal Antibody                                 | Sema3A antibody                                                                        | 2030                     |\n| BI 836880                          | NBE           | Recombinant Proteins                                | VEGF / ANG2 bispecific antibody                                                        | n/a                      |\n| BI 771716                          | NBE           | Recombinant Proteins                                | Anti-C3 antibody fragment                                                              | 2030                     |\n| Obrixtamig (BI 764532)            | NBE (ntm)     | T-cell Engager                                      | DLL3/CD3 bispecific antibody                                                           | 2028                     |\n| BI 765063                          | NBE (ntm)     | T-cell Engager                                      | Immuno-oncology agent                                                                  | post 2033            |\n| BI 765049                          | NBE (ntm)     | T-cell Engager                                      | B7-H6/CD3 bispecific antibody                                                          | 2027                     |\n| BI 765179                          | NBE           | Monoclonal Antibody                                 | CD137/FAP agonist antibody                                                             | 2030                     |\n| BI 765250                          | NBE           | Monoclonal Antibody                                 | PD-1 agonist                                                                           | 2033                     |\n| BI 765423                          | NBE           | Monoclonal Antibody                                 | Anti-IL11 antibody                                                                     | 2031                     |\n| BI 1703880                         | NCE (liquid)  | Small Molecule                                      | Not specified                                                                          | 2031                     |\n| BI 1831169                         | NBE (ntm)     | Gene Therapy                                        | VSV-GP OV (Oncolytic Virus)                                                            | 2029                     |\n| BI 1821736                         | NBE (ntm)     | Gene Therapy                                        | VSV-GP-CD80-Fc OV                                                                      | 2030                     |\n| BI 3006337                         | NCE (liquid)  | Peptides                                            | GLP-1/FGF21 agonist                                                                    | 2033                     |\n| BI 754132                          | NCE (solid)   | Small Molecule                                      | TrkB activator                                                                         | post 2033            |\n| BI 1584862                         | NCE (solid)   | Small Molecule                                      | PAFR antagonist                                                                        | 2032                     |\n| BI 1815368                         | NCE (solid)   | Small Molecule                                      | PKK inhibitor                                                                          | 2032                     |\n| BI 1839100                         | NCE (solid)   | Small Molecule                                      | TRPA1 inhibitor                                                                        | 2029                     |\n| Ezabenlimab                        | NBE           | Monoclonal Antibody                                 | PD-1-targeting monoclonal antibody                                                     | post 2030            |\n| BI 3706674                         | NCE (solid)   | Small Molecule                                      | GDP KRAS inhibitor                                                                     | 2029                     |\n| BI 3018078 / BI 3024308           | NBE (ntm)     | Gene Therapy                                        | ATP128 + VCV-GP128 combo                                                               | 2032                     |\n| BI 3810539                         | NBE           | ADC                                                 | DLL3 ADC                                                                               | 2033                     |\n| BI 3810944                         | NBE           | Recombinant Proteins                                | ODC-IL12 (cytokine-based therapy)                                                      | 2031                     |\n| BI 3907074 / 3907075 / 3720590    | NBE (ntm)     | Gene Therapy                                        | ATP150/ATP152 + VSV-GP154 combo                                                        | 2031                     |\n| BI 3923948                         | NBE (ntm)     | Gene Therapy                                        | VSV-GP-GSDME-IL12                                                                      | 2034            |\n| BI 765883                          | NBE           | Monoclonal Antibody                                 | TRAILR2/CDH3 Antibody                                                                  | 2033                     |\n| BI 3034701                         | NCE (liquid)  | Peptides                                            | GLP-1R/GIPR/NPY2R tri-agonist                                                          | 2032                     |\n| BI 3060292                         | NCE (liquid)  | Small Molecule                                      | NMUR2 agonist                                                                          | 2033                     |\n| BI 3802876                         | NBE           | Recombinant Proteins                                | FAP-TRAILR2 agonist                                                                    | 2035                     |\n| BI 3804379                         | NBE           | Recombinant Proteins                                | Not specified                                                                          | 2037                     |\n| BI 3906517                         | NCE (solid)   | Small Molecule                                      | LG3RA (Leptin receptor antagonist)                                                     | Not specified            |\n| BI 1356225                         | NCE (solid)   | Small Molecule                                      | GOAT inhibitor                                                                         | 2034            |\n| BI 3031185                         | NCE (solid)   | Small Molecule                                      | mGluR4 NAM                                                                             | 2035                     |\n| BI 3776528                         | NCE (solid)   | Small Molecule                                      | SSTR4 agonist                                                                          | 2036                     |\n| BI 3793898                         | NCE (solid)   | Small Molecule                                      | mGluR3 PAM                                                                             | Not specified            |\n| BI 3000202                         | NCE (solid)   | Small Molecule                                      | cGAS inhibitor                                                                         | 2033                     |\n| BI 3009947                         | NCE (solid)   | Small Molecule                                      | STING inhibitor                                                                        | Not specified            |\n| BI 3794407                         | NCE (solid)   | Small Molecule                                      | cGAS inhibitor                                                                         | Not specified            |\n| BI 3731579                         | NCE (solid)   | Small Molecule                                      | NOX4 inhibitor                                                                         | 2033                     |\n| BI 3720931                         | NBE (ntm)     | Gene Therapy                                        | Lentiviral vector-based gene therapy                                                   | 2029                     |\n| BI 3810477                         | NBE           | Monoclonal Antibody                                 | Anti-CTGF antibody                                                                     | 2034            |\n| BI 765243                          | NBE           | Recombinant Proteins                                | TrkB/anti-VEGF bispecific                                                              | Not specified            |\n| BI 765128                          | NBE           | Monoclonal Antibody                                 | Anti-NRP1 antibody                                                                     | 2030                     |",
      "created_at": "2025-09-04T14:28:18.221584+00:00"
    }
  ],
  "modalities": [
    {
      "modality_id": 5,
      "modality_name": "ADC",
      "modality_category": "Engineered Biologics",
      "label": "NBE",
      "short_description": "Antibody-Drug Conjugates represent a complex dual-stream manufacturing scenario, combining biologics manufacturing with HPAPI (cytotoxic payload) synthesis. Rapid growth segment expanding into non-oncology applications. Requires site-specific conjugation technologies, OEB4 containment for payload, and advanced analytics to control drug-to-antibody ratio (DAR).",
      "description": "",
      "standard_challenges": [
        "Antibody-Drug Conjugate (ADC) Manufacturing",
        "High-Potency Active Pharmaceutical Ingredient (HPAPI) Handling"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 10,
      "modality_name": "Bacteria",
      "modality_category": "Advanced Therapy",
      "label": "NBE (ntm)",
      "short_description": "Live biotherapeutics including engineered bacteria for therapeutic applications. Requires specialized containment and controlled atmosphere processing, bacterial fermentation capabilities, and unique regulatory considerations for living organisms. Emerging field with growing pipeline especially in microbiome and oncology applications.",
      "description": "",
      "standard_challenges": [
        "Live Organism Manufacturing",
        "Specialized Containment",
        "Bacterial Fermentation"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 15,
      "modality_name": "Base/Prime Editing",
      "modality_category": "Emerging Therapy",
      "label": "NBE (ntm)",
      "short_description": "Precise genetic modifications beyond traditional CRISPR with improved specificity and reduced off-target effects. Next-generation gene editing technologies offering more precise therapeutic interventions. Requires specialized delivery systems and advanced manufacturing for editing components.",
      "description": "",
      "standard_challenges": [
        "Precision Gene Editing Manufacturing",
        "Advanced Delivery Systems",
        "Component Stability"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 12,
      "modality_name": "CAR-NK",
      "modality_category": "Emerging Therapy",
      "label": "NBE (ntm)",
      "short_description": "CAR-Natural Killer cell therapies offering manufacturing advantages over CAR-T with potential for allogeneic approaches. In vivo approaches are being developed to reduce manufacturing complexity. Alternative to CAR-T for solid tumor applications with potentially broader clinical utility and reduced manufacturing burden.",
      "description": "",
      "standard_challenges": [
        "Cell Engineering",
        "Allogeneic Processing",
        "In Vivo Delivery"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 9,
      "modality_name": "Gene Therapy",
      "modality_category": "Advanced Therapy",
      "label": "NBE (ntm)",
      "short_description": "Genetic material modification approaches including AAV vectors, lentiviral vectors, and oncolytic viruses (OV/CV). Beyond BSL-2+ containment requirements, requires specialized cell culture systems for viral replication, advanced purification to separate viral particles from cell debris, extensive viral safety testing (e.g., for RCV), and complex process development.",
      "description": "",
      "standard_challenges": [
        "Viral Vector / Gene Therapy Manufacturing",
        "BSL-2+ Containment Facilities required",
        "Viral Safety Testing"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 2,
      "modality_name": "Monoclonal Antibody",
      "modality_category": "Biologics",
      "label": "NBE",
      "short_description": "Standard monoclonal antibodies (mAbs) targeting specific antigens. Largest established biologics class, expanding beyond oncology into Alzheimer's and other indications. Requires cell culture systems, downstream purification, and cold chain logistics. Well-established manufacturing processes but requires high titer production and complex purification.",
      "description": "",
      "standard_challenges": [
        "High Titer Production",
        "Downstream Purification",
        "Cold Chain Logistics"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 7,
      "modality_name": "PROTAC",
      "modality_category": "Engineered Biologics",
      "label": "NCE (solid)",
      "short_description": "Proteolysis Targeting Chimeras are targeted protein degraders representing the fastest growing market segment. Highly complex manufacturing involving multi-component synthesis, precise linker chemistry, and advanced purification for high molecular weight (>1000 Da) compounds. Pose significant formulation and bioavailability challenges while targeting previously 'undruggable' proteins.",
      "description": "",
      "standard_challenges": [
        "PROTAC Manufacturing",
        "Complex Synthesis",
        "Advanced Formulation"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 11,
      "modality_name": "Oligonucleotides",
      "modality_category": "Nucleic Acids",
      "label": "NCE (liquid)",
      "short_description": "Gene expression modulation therapies including antisense oligonucleotides (ASOs) that bind mRNA to inhibit translation/alter splicing, small interfering RNA (siRNA) that induce target mRNA degradation, and messenger RNA (mRNA) therapies that deliver therapeutic proteins. Requires specialized solid-phase synthesis, complex HPLC purification, stability management, and delivery system integration (LNPs, conjugates).",
      "description": "",
      "standard_challenges": [
        "Specialized Solid-Phase Synthesis",
        "Complex Purification",
        "Delivery System Integration",
        "Stability Management"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 3,
      "modality_name": "Peptides",
      "modality_category": "Biologics",
      "label": "NCE (liquid)",
      "short_description": "Therapeutic peptides including multi-agonists, modified peptides, and peptide drug conjugates. Requires specialized Solid-Phase Peptide Synthesis (SPPS), advanced purification, and precise control of stereochemistry. Examples include GLP-1R/GIPR agonists like Survodutide. Often requires device integration for delivery and cold chain management.",
      "description": "",
      "standard_challenges": [
        "Advanced Peptide Manufacturing",
        "Device & Combination Product Manufacturing",
        "Cold Chain Logistics"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 6,
      "modality_name": "Recombinant Proteins",
      "modality_category": "Biologics",
      "label": "NBE",
      "short_description": "Engineered proteins including fusion proteins, complex receptor modulators, and proteins that are not standard monoclonal antibodies. Requires specialized process development for expression, purification, and analytical characterization to ensure proper structure and function. Examples include DcR3-Fc fusion proteins and FZD4_LRP5 modulators.",
      "description": "",
      "standard_challenges": [
        "Complex Biologics Manufacturing",
        "Advanced Purification"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 1,
      "modality_name": "Small Molecule",
      "modality_category": "Traditional",
      "label": "NCE (solid)",
      "short_description": "Traditional chemically synthesized compounds (NCEs - New Chemical Entities). Steady FDA approval rates with well-established manufacturing processes including synthesis, purification, and formulation. Includes compounds requiring high-selectivity synthesis, covalent inhibitor stability management, and specialized formulations like amorphous solid dispersions for poorly soluble compounds.",
      "description": "",
      "standard_challenges": [
        "High-Selectivity Synthesis",
        "Covalent Inhibitor Stability",
        "Amorphous Solid Dispersion Manufacturing"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 4,
      "modality_name": "T-cell Engager",
      "modality_category": "Engineered Biologics",
      "label": "NBE (ntm)",
      "short_description": "Bispecific antibodies that engage T-cells to target cancer cells through two-target engagement mechanisms. Requires complex protein engineering and specialized expression systems (e.g., BI-HEX\u00ae platform) to ensure correct heavy/light chain pairing and prevent mispairing and aggregation. Examples include B7-H6/CD3 and ALPG/CD3 T-cell engagers.",
      "description": "",
      "standard_challenges": [
        "Bispecific/Multi-specific Antibody Manufacturing",
        "Complex Biologics Manufacturing"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 13,
      "modality_name": "TCR-T",
      "modality_category": "Emerging Therapy",
      "label": "NBE (ntm)",
      "short_description": "T-cell Receptor therapies designed for solid tumor applications, broadening clinical utility beyond CAR-T applications. Requires T-cell engineering with TCR modification, specialized processing similar to CAR-T but with different target recognition mechanisms. Growing pipeline for solid tumor indications.",
      "description": "",
      "standard_challenges": [
        "T-cell Engineering",
        "Solid Tumor Targeting",
        "TCR Manufacturing"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 14,
      "modality_name": "Trispecific Antibodies",
      "modality_category": "Emerging Biologics",
      "label": "NBE",
      "short_description": "Three-target engagement antibodies for enhanced cancer immunotherapy efficacy. Even more complex than bispecific antibodies, requiring sophisticated protein engineering to ensure correct multi-chain pairing and prevent aggregation. Novel therapeutic mechanisms with enhanced specificity and efficacy potential.",
      "description": "",
      "standard_challenges": [
        "Multi-specific Antibody Manufacturing",
        "Complex Protein Engineering",
        "Advanced Analytics"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 8,
      "modality_name": "CAR-T",
      "modality_category": "Advanced Therapy",
      "label": "NBE (ntm)",
      "short_description": "Chimeric Antigen Receptor T-cell therapies, a form of personalized immunotherapy established in hematologic malignancies. Requires autologous cell collection and processing, viral transduction for CAR gene insertion, controlled cell expansion, quality control, cryopreservation, and patient-specific logistics with extremely tight timelines. Highest manufacturing complexity due to personalized medicine requirements.",
      "description": "",
      "standard_challenges": [
        "Personalized Manufacturing",
        "Autologous Cell Processing",
        "Viral Transduction",
        "Cryopreservation",
        "Patient-Specific Logistics"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 16,
      "modality_name": "Molecular Glues",
      "modality_category": "Emerging Biologics",
      "label": "NCE (solid)",
      "short_description": "Novel protein degradation approach targeting previously 'undruggable' proteins through induced protein-protein interactions. Different mechanism from PROTACs but similar complexity in targeting protein degradation pathways. Requires specialized synthesis and formulation approaches.",
      "description": "",
      "standard_challenges": [
        "Novel Protein Degradation Manufacturing",
        "Specialized Synthesis",
        "Target Validation"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 17,
      "modality_name": "Radiopharmaceuticals",
      "modality_category": "Emerging Therapy",
      "label": "NCE (liquid)",
      "short_description": "Targeted radioactive isotope delivery for cancer therapy. Requires specialized facilities for radioactive material handling, precise isotope incorporation, short half-life management, and specialized containment and logistics. Growing field for targeted cancer treatment with unique manufacturing and regulatory challenges.",
      "description": "",
      "standard_challenges": [
        "Radioactive Material Handling",
        "Isotope Manufacturing",
        "Specialized Containment",
        "Short Half-Life Logistics"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 18,
      "modality_name": "Stem Cell Therapies",
      "modality_category": "Advanced Therapy",
      "label": "NBE (ntm)",
      "short_description": "Tissue repair and regenerative applications using various stem cell types. Growing pipeline especially in oncology and rare diseases. Requires specialized cell culture, cell banking, quality control for cellular products, and often autologous or allogeneic processing depending on application.",
      "description": "",
      "standard_challenges": [
        "Stem Cell Culture",
        "Cell Banking",
        "Regenerative Manufacturing",
        "Cellular Quality Control"
      ],
      "created_at": "2025-09-22T07:54:32.809167+00:00"
    },
    {
      "modality_id": 19,
      "modality_name": "Prescription Digital Therapeutic (SaMD/PDT)",
      "modality_category": "Digital Therapeutics",
      "label": "DTx",
      "short_description": "Software-based medical interventions regulated as Software as a Medical Device (SaMD). Prescription Digital Therapeutics (PDTs) deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease. Delivered via mobile or web platforms, often adjunctive to pharmacotherapy, and require clinical validation through RCTs.",
      "description": "Digital therapeutics represent a new class of regulated medical products that use software to achieve therapeutic outcomes. Unlike wellness apps, PDTs undergo rigorous clinical evaluation and regulatory review. They require compliance with SaMD standards (e.g., IEC 62304), cybersecurity, data privacy (GDPR/HIPAA), and integration into healthcare workflows. Common use cases include mental health, chronic disease management, and adjunctive therapy in CNS disorders.",
      "standard_challenges": [
        "Regulatory compliance for SaMD (FDA, EMA, MDR)",
        "Quality Management System (QMS) for software lifecycle",
        "Cybersecurity and data privacy (GDPR, HIPAA)",
        "Clinical validation and real-world evidence generation",
        "Patient engagement and adherence",
        "Payer coverage and reimbursement pathways"
      ],
      "created_at": "2025-09-25T14:30:00+00:00"
    }
  ],
  "process_stages": [
    {
      "stage_id": 1,
      "stage_name": "Drug Substance (DS) Manufacturing",
      "stage_category": "Core Process",
      "short_description": "Production of active pharmaceutical ingredient (API)",
      "description": "All stages involved in producing the drug substance, from initial synthesis or cell culture to final purification and isolation. Encompasses upstream production, downstream purification, and API finishing.",
      "parent_stage_id": null,
      "hierarchy_level": 1,
      "stage_order": 1
    },
    {
      "stage_id": 2,
      "stage_name": "Drug Product (DP) Manufacturing",
      "stage_category": "Core Process",
      "short_description": "Conversion of API into final dosage form",
      "description": "Process of converting drug substance into final dosage form suitable for patient administration, including formulation development, manufacturing operations, fill-finish, and packaging.",
      "parent_stage_id": null,
      "hierarchy_level": 1,
      "stage_order": 2
    },
    {
      "stage_id": 3,
      "stage_name": "Process Technology & Quality Systems",
      "stage_category": "Support Process",
      "short_description": "Cross-cutting systems ensuring process control and compliance",
      "description": "Overarching principles and systems governing all manufacturing stages, ensuring processes are controlled, validated, and compliant with global regulatory standards including GMP and ICH guidelines.",
      "parent_stage_id": null,
      "hierarchy_level": 1,
      "stage_order": 3
    },
    {
      "stage_id": 4,
      "stage_name": "Upstream Processing",
      "stage_category": "Drug Substance",
      "short_description": "Initial production phase - synthesis or cell culture",
      "description": "Initial phase where drug substance is created through chemical synthesis (small molecules), biological production (cell culture for proteins), or specialized processing (advanced therapies). Includes all activities from raw materials to crude product.",
      "parent_stage_id": 1,
      "hierarchy_level": 2,
      "stage_order": 1
    },
    {
      "stage_id": 5,
      "stage_name": "Downstream Processing",
      "stage_category": "Drug Substance",
      "short_description": "Recovery, purification, and isolation of drug substance",
      "description": "Recovery, purification, and isolation of drug substance from complex upstream mixture. Achieves required purity and concentration while removing process-related and product-related impurities. Can account for 50-80% of biologics manufacturing costs.",
      "parent_stage_id": 1,
      "hierarchy_level": 2,
      "stage_order": 2
    },
    {
      "stage_id": 6,
      "stage_name": "Drug Substance Finishing",
      "stage_category": "Drug Substance",
      "short_description": "Final API processing and preparation for storage",
      "description": "Final preparation of purified API for storage or transfer to DP manufacturing. Includes physical processing (drying, milling, blending), comprehensive quality control testing, and establishment of appropriate storage conditions with stability programs.",
      "parent_stage_id": 1,
      "hierarchy_level": 2,
      "stage_order": 3
    },
    {
      "stage_id": 7,
      "stage_name": "Formulation Development",
      "stage_category": "Drug Product",
      "short_description": "Design of stable, effective drug product formulation",
      "description": "Creating stable, effective, and safe drug product by combining drug substance with selected excipients. Optimized for target delivery route (oral, injectable, etc.) with focus on stability, bioavailability, and patient acceptability.",
      "parent_stage_id": 2,
      "hierarchy_level": 2,
      "stage_order": 1
    },
    {
      "stage_id": 8,
      "stage_name": "Manufacturing Operations",
      "stage_category": "Drug Product",
      "short_description": "Large-scale production of final dosage form",
      "description": "Large-scale execution of developed formulation process to produce final dosage form. Includes unit operations such as blending, granulation, compression, coating (solids) or aseptic processing (injectables), conducted under appropriate GMP conditions.",
      "parent_stage_id": 2,
      "hierarchy_level": 2,
      "stage_order": 2
    },
    {
      "stage_id": 9,
      "stage_name": "Fill-Finish & Packaging",
      "stage_category": "Drug Product",
      "short_description": "Final container filling, sealing, and packaging",
      "description": "Final step where manufactured drug product is filled into primary container, sealed, inspected, and packaged for distribution. Includes serialization for track-and-trace, cold chain management for biologics, and integration with delivery devices.",
      "parent_stage_id": 2,
      "hierarchy_level": 2,
      "stage_order": 3
    },
    {
      "stage_id": 10,
      "stage_name": "Process Development & Scale-Up",
      "stage_category": "Quality Systems",
      "short_description": "Process design and commercial scale transfer",
      "description": "Activities to design robust manufacturing process and successfully transfer from laboratory scale to commercial production. Utilizes Quality by Design (QbD) principles, Design of Experiments (DoE), and risk-based validation strategies.",
      "parent_stage_id": 3,
      "hierarchy_level": 2,
      "stage_order": 1
    },
    {
      "stage_id": 11,
      "stage_name": "Quality Control & Analytics",
      "stage_category": "Quality Systems",
      "short_description": "Analytical methods and process monitoring",
      "description": "Analytical methods and systems for monitoring and controlling manufacturing process and ensuring final product quality. Includes traditional laboratory testing, Process Analytical Technology (PAT), and advanced techniques per ICH Q2(R2) and Q14 guidelines.",
      "parent_stage_id": 3,
      "hierarchy_level": 2,
      "stage_order": 2
    },
    {
      "stage_id": 12,
      "stage_name": "Regulatory Framework & Compliance",
      "stage_category": "Quality Systems",
      "short_description": "GMP compliance and regulatory adherence",
      "description": "Regulatory framework ensuring patient safety and product efficacy through Current Good Manufacturing Practice (GMP), Chemistry Manufacturing and Controls (CMC) submissions, and harmonized international standards (ICH, FDA, EMA).",
      "parent_stage_id": 3,
      "hierarchy_level": 2,
      "stage_order": 3
    },
    {
      "stage_id": 13,
      "stage_name": "Chemical/Biological Production",
      "stage_category": "Production",
      "short_description": "Core synthesis or culture operations",
      "description": "Primary production activities including multi-step organic synthesis for small molecules, mammalian/microbial cell culture for biologics, or specialized production for advanced therapies. Requires precise control of critical process parameters.",
      "parent_stage_id": 4,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 14,
      "stage_name": "Process Intensification",
      "stage_category": "Production",
      "short_description": "Advanced production optimization techniques",
      "description": "Advanced techniques to improve productivity and efficiency including continuous processing, perfusion culture systems, flow chemistry, or process analytical technology for real-time optimization.",
      "parent_stage_id": 4,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 15,
      "stage_name": "Cell Line Development",
      "stage_category": "Biologics",
      "short_description": "Generation of production cell lines",
      "description": "Development of stable, high-producing cell lines for biologics. Includes host cell selection (CHO, HEK293, E. coli), genetic engineering, clonal selection, and establishment of Master and Working Cell Banks. Modern platforms using CRISPR/Cas9 can achieve stable lines in 12 weeks.",
      "parent_stage_id": 4,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 16,
      "stage_name": "Primary Recovery & Clarification",
      "stage_category": "Purification",
      "short_description": "Initial separation and clarification",
      "description": "Initial recovery of product from reaction mixture or cell culture fluid. Includes harvest operations, depth filtration, centrifugation, or solvent extraction to achieve clarified intermediate (typically >95% recovery, <10 NTU turbidity for biologics).",
      "parent_stage_id": 5,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 17,
      "stage_name": "Chromatography & Advanced Purification",
      "stage_category": "Purification",
      "short_description": "High-resolution purification steps",
      "description": "Advanced purification using multiple chromatography modes (affinity, ion exchange, hydrophobic interaction, size exclusion), crystallization, or specialty techniques. Multi-step platforms achieve target purity specifications while removing impurities and variants.",
      "parent_stage_id": 5,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 18,
      "stage_name": "Conjugation & Modification",
      "stage_category": "Purification",
      "short_description": "Post-production molecular modifications",
      "description": "Chemical or enzymatic modifications performed on purified molecules. Includes antibody-drug conjugation (ADCs), PEGylation, glycoengineering, or other post-translational modifications. Requires subsequent purification to achieve target drug-to-antibody ratio or modification level.",
      "parent_stage_id": 5,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 19,
      "stage_name": "Viral Safety & Impurity Clearance",
      "stage_category": "Purification",
      "short_description": "Safety-critical clearance steps",
      "description": "Dedicated steps for viral inactivation and removal, plus clearance of process and product-related impurities. For biologics includes low pH viral inactivation, solvent/detergent treatment, and 20nm viral filtration. Critical for patient safety.",
      "parent_stage_id": 5,
      "hierarchy_level": 3,
      "stage_order": 4
    },
    {
      "stage_id": 20,
      "stage_name": "Physical Processing & Drying",
      "stage_category": "API Finishing",
      "short_description": "Controlled drying and particle engineering",
      "description": "Controlled drying operations (vacuum, fluid bed, spray drying) to remove solvents and achieve target moisture content. Includes particle engineering via milling, micronization, or spray techniques to control particle size distribution and morphology.",
      "parent_stage_id": 6,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 21,
      "stage_name": "Quality Control Release Testing",
      "stage_category": "API Finishing",
      "short_description": "Comprehensive API testing and release",
      "description": "Comprehensive analytical testing to verify drug substance meets all specifications for identity, purity, assay, impurity profiles, physical properties, and stability before release. Performed according to validated methods per compendial and regulatory requirements.",
      "parent_stage_id": 6,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 22,
      "stage_name": "Storage & Stability Management",
      "stage_category": "API Finishing",
      "short_description": "Controlled storage and stability programs",
      "description": "Storage of finished drug substance under validated conditions (temperature, humidity, light protection). Supported by ICH-compliant stability programs to establish retest dates or expiry. Biologics often require -70\u00b0C, small molecules may be ambient or refrigerated.",
      "parent_stage_id": 6,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 23,
      "stage_name": "Excipient Selection & Optimization",
      "stage_category": "Formulation",
      "short_description": "Selection of stabilizers and delivery enhancers",
      "description": "Selection and optimization of excipients, buffers, stabilizers, surfactants, and delivery system components. For biologics: buffer systems (histidine, citrate), stabilizers (sucrose, trehalose), surfactants (polysorbate). For small molecules: disintegrants, binders, lubricants.",
      "parent_stage_id": 7,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 24,
      "stage_name": "Physical Form Development",
      "stage_category": "Formulation",
      "short_description": "Solid form, particle engineering, delivery systems",
      "description": "Development of appropriate physical form and delivery system. Options include crystalline/amorphous solids, solid dispersions, lipid-based systems, nanoparticles (LNPs for mRNA), liposomes, or combination products. Critical for bioavailability and stability.",
      "parent_stage_id": 7,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 25,
      "stage_name": "Formulation Characterization & Stability",
      "stage_category": "Formulation",
      "short_description": "Analytical characterization and stability assessment",
      "description": "Comprehensive characterization of formulation including physical properties (pH, osmolality, particle size, viscosity), chemical stability, and compatibility. Accelerated and long-term stability studies establish shelf-life and storage conditions.",
      "parent_stage_id": 7,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 26,
      "stage_name": "Solid Dosage Manufacturing",
      "stage_category": "Oral Dosage",
      "short_description": "Tablet and capsule production",
      "description": "Production of oral solid dosage forms through blending, granulation (wet/dry/continuous), compression or encapsulation, and coating. Modern operations increasingly use continuous manufacturing platforms integrating all unit operations.",
      "parent_stage_id": 8,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 27,
      "stage_name": "Aseptic Processing",
      "stage_category": "Sterile Manufacturing",
      "short_description": "Sterile product manufacturing",
      "description": "Manufacturing of sterile injectables in Class A/B cleanroom environments with laminar airflow. Includes sterile filtration (0.22\u03bcm), aseptic transfer using single-use systems, and environmental monitoring to prevent microbial contamination.",
      "parent_stage_id": 8,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 28,
      "stage_name": "Personalized/Autologous Manufacturing",
      "stage_category": "Advanced Therapy",
      "short_description": "Patient-specific cell therapy production",
      "description": "Highly complex vein-to-vein manufacturing for autologous cell therapies. Includes patient cell collection, isolation, genetic modification, ex-vivo expansion (7-14 days), and cryopreservation. Requires rigorous chain-of-identity and contamination control. Current timelines 3-5 weeks.",
      "parent_stage_id": 8,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 29,
      "stage_name": "Continuous Manufacturing Integration",
      "stage_category": "Advanced Manufacturing",
      "short_description": "End-to-end continuous processing",
      "description": "Integration of continuous unit operations from API synthesis through final dosage form. Requires real-time monitoring, material traceability, residence time distribution modeling, and advanced control strategies per ICH Q13 guidance.",
      "parent_stage_id": 8,
      "hierarchy_level": 3,
      "stage_order": 4
    },
    {
      "stage_id": 30,
      "stage_name": "Primary Container Filling",
      "stage_category": "Fill-Finish",
      "short_description": "Vial, syringe, or device filling operations",
      "description": "Precision filling into primary containers using time-pressure filling, peristaltic pumps, or rotary piston systems. For biologics: aseptic filling into vials, pre-filled syringes, or cartridges. Includes automated weight checks and in-process controls.",
      "parent_stage_id": 9,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 31,
      "stage_name": "Lyophilization & Stabilization",
      "stage_category": "Fill-Finish",
      "short_description": "Freeze-drying for stability enhancement",
      "description": "Freeze-drying of unstable liquid biologics to create stable powder formulations. Controlled process includes freezing, primary drying under vacuum, and secondary drying to achieve residual moisture <3%. Extends shelf-life and enables ambient storage.",
      "parent_stage_id": 9,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 32,
      "stage_name": "Container Closure & Device Integration",
      "stage_category": "Fill-Finish",
      "short_description": "Sealing and combination product assembly",
      "description": "Container closure (stoppers, caps, seals) and integration with delivery devices (auto-injectors, pen injectors, inhalers). Requires container closure integrity testing and functionality testing. For cell therapies: controlled-rate freezing and cryogenic storage (-150\u00b0C to -196\u00b0C).",
      "parent_stage_id": 9,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 33,
      "stage_name": "Visual Inspection & Quality Verification",
      "stage_category": "Fill-Finish",
      "short_description": "100% inspection for defects",
      "description": "Automated visual inspection systems examine each unit for particulates, fill volume, container defects, and closure integrity. Uses high-resolution cameras and machine vision. Complemented by manual inspection for complex defects. Rejection criteria per compendial standards.",
      "parent_stage_id": 9,
      "hierarchy_level": 3,
      "stage_order": 4
    },
    {
      "stage_id": 34,
      "stage_name": "Secondary Packaging & Serialization",
      "stage_category": "Fill-Finish",
      "short_description": "Labeling, packaging, and track-trace",
      "description": "Secondary and tertiary packaging with product labeling. Serialization adds unique identifiers at unit, bundle, and case levels for supply chain security and anti-counterfeiting per DSCSA/FMD regulations. Aggregation links parent-child relationships through packaging hierarchy.",
      "parent_stage_id": 9,
      "hierarchy_level": 3,
      "stage_order": 5
    },
    {
      "stage_id": 35,
      "stage_name": "Cold Chain & Distribution",
      "stage_category": "Fill-Finish",
      "short_description": "Temperature-controlled logistics",
      "description": "Unbroken cold chain management (2-8\u00b0C or frozen) from manufacturing through distribution. Uses qualified shipping containers with continuous temperature monitoring, mapped shipping lanes, and contingency protocols. Critical for biologics and advanced therapies to maintain product integrity.",
      "parent_stage_id": 9,
      "hierarchy_level": 3,
      "stage_order": 6
    },
    {
      "stage_id": 36,
      "stage_name": "Quality by Design (QbD) Implementation",
      "stage_category": "Process Development",
      "short_description": "Systematic process understanding and design",
      "description": "Systematic approach beginning with Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). Uses Design of Experiments (DoE) to establish design space and develop control strategy per ICH Q8/Q9/Q10.",
      "parent_stage_id": 10,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 37,
      "stage_name": "Technology Transfer & Scale-Up",
      "stage_category": "Process Development",
      "short_description": "Lab to commercial scale progression",
      "description": "Progression from pilot scale to commercial manufacturing (e.g., 200L to 20,000L bioreactors, batch to continuous). Requires comprehensive documentation, cross-functional teams, process validation with minimum three consecutive commercial batches, and comparability assessment.",
      "parent_stage_id": 10,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 38,
      "stage_name": "Supply Chain Risk Management",
      "stage_category": "Process Development",
      "short_description": "Risk mitigation and supplier diversification",
      "description": "Mapping and securing supply chain for critical materials and services. Includes supplier qualification, dual-sourcing strategies, inventory management, and AI-powered risk monitoring tools to mitigate geopolitical risks, natural disasters, and cybersecurity threats.",
      "parent_stage_id": 10,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 39,
      "stage_name": "Process Analytical Technology (PAT)",
      "stage_category": "Analytics",
      "short_description": "Real-time process monitoring and control",
      "description": "In-line, on-line, or at-line analytical techniques (NIR, Raman spectroscopy, focused beam reflectance measurement) providing real-time monitoring of CPPs. Enables proactive quality management, reduces cycle times, and supports real-time release testing (RTRT).",
      "parent_stage_id": 11,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 40,
      "stage_name": "Advanced Analytical Methods",
      "stage_category": "Analytics",
      "short_description": "Sophisticated characterization techniques",
      "description": "Advanced methods for comprehensive product characterization. For biologics: Multi-Attribute Methods (MAM), mass spectrometry for post-translational modifications, higher-order structure analysis. For small molecules: impurity profiling, polymorph analysis. All methods validated per ICH Q2(R2) and Q14.",
      "parent_stage_id": 11,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 41,
      "stage_name": "Stability & Comparability Studies",
      "stage_category": "Analytics",
      "short_description": "Long-term product monitoring",
      "description": "ICH-compliant stability programs establishing shelf-life and storage conditions through accelerated and long-term studies. Comparability studies demonstrate manufacturing changes don't adversely impact quality. Uses risk-based approaches per ICH Q9 to determine study scope.",
      "parent_stage_id": 11,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 42,
      "stage_name": "Current Good Manufacturing Practice (cGMP)",
      "stage_category": "Regulatory Compliance",
      "short_description": "Core GMP requirements and systems",
      "description": "Fundamental regulatory standard governing all aspects: facility design, equipment qualification/validation, personnel training, documentation systems, batch records, change control, deviation management, CAPA, and quality systems. Ensures consistent quality and patient safety.",
      "parent_stage_id": 12,
      "hierarchy_level": 3,
      "stage_order": 1
    },
    {
      "stage_id": 43,
      "stage_name": "CMC Regulatory Submissions",
      "stage_category": "Regulatory Compliance",
      "short_description": "Chemistry, Manufacturing, and Controls documentation",
      "description": "Comprehensive documentation of manufacturing process, analytical methods, specifications, and quality systems for regulatory submissions (IND, NDA, BLA, MAA). Follows electronic Common Technical Document (eCTD) format for FDA, EMA, and other agencies.",
      "parent_stage_id": 12,
      "hierarchy_level": 3,
      "stage_order": 2
    },
    {
      "stage_id": 44,
      "stage_name": "Regulatory Inspections & Compliance",
      "stage_category": "Regulatory Compliance",
      "short_description": "Inspection readiness and remediation",
      "description": "Preparation for and response to regulatory inspections (FDA, EMA, local authorities). Includes mock audits, continuous compliance monitoring, rapid CAPA implementation for observations, and maintaining inspection readiness through robust quality systems.",
      "parent_stage_id": 12,
      "hierarchy_level": 3,
      "stage_order": 3
    },
    {
      "stage_id": 45,
      "stage_name": "International Harmonization & Standards",
      "stage_category": "Regulatory Compliance",
      "short_description": "Global regulatory alignment",
      "description": "Implementation of harmonized international standards (ICH Q7, Q8-Q13, Q2(R2), Q14) enabling consistent requirements across regions. Includes participation in regulatory working groups, adoption of new guidelines, and leveraging mutual recognition agreements to streamline global development.",
      "parent_stage_id": 12,
      "hierarchy_level": 3,
      "stage_order": 4
    }
  ],
  "manufacturing_capabilities": [
    {
      "capability_id": 1,
      "capability_name": "Multi-Step Organic Synthesis",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Expertise in complex multi-step chemical transformations for small molecule API synthesis including protection/deprotection strategies, coupling reactions, and advanced organic chemistry techniques",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 2,
      "capability_name": "Asymmetric Synthesis",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Specialized capability for stereoselective synthesis of chiral molecules using catalytic methods, chiral auxiliaries, or enzymatic approaches. Critical for producing single enantiomers with high optical purity",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 3,
      "capability_name": "Transition Metal Catalysis",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Advanced expertise in transition metal-catalyzed reactions (Pd, Pt, Rh, Ru) for C-C bond formation, hydrogenation, and complex transformations. Requires specialized handling and recovery systems",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 4,
      "capability_name": "Heterocyclic Chemistry",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Specialized knowledge in synthesis and manipulation of heterocyclic ring systems common in pharmaceutical APIs. Essential for most modern small molecule drugs",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 5,
      "capability_name": "Cryogenic Reaction Control",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Capability to conduct reactions at extremely low temperatures (down to -78\u00b0C or lower) with precise temperature control for sensitive transformations and reactive intermediates",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 6,
      "capability_name": "Continuous Flow Chemistry",
      "capability_category": "Process Technology",
      "approach_category": "Advanced",
      "description": "Expertise in continuous chemical synthesis using microreactors and flow systems for improved reaction control, safety, and consistency. Enables process intensification for small molecules",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 7,
      "capability_name": "Large-Scale Hydrogenation",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Industrial-scale capability for high-pressure catalytic hydrogenation using precious metal catalysts with appropriate safety controls and catalyst recovery systems",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 8,
      "capability_name": "Advanced Click Chemistry",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Expertise in click chemistry reactions (CuAAC, SPAAC, thiol-ene) and SuFEx chemistry for efficient molecular assembly. Critical for PROTACs and complex conjugates",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 9,
      "capability_name": "PROTAC Synthesis",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Upstream",
      "description": "Specialized capability for synthesizing targeted protein degraders requiring 24+ synthetic steps with complex linker chemistry and three-component molecular assembly (>900 Da)",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 10,
      "capability_name": "High-Potency API Handling",
      "capability_category": "Safety & Containment",
      "approach_category": "Facility",
      "description": "Containment facilities and protocols for handling highly potent compounds (OEL <1 \u03bcg/m\u00b3) including cytotoxics for ADCs. Requires dedicated suites with negative pressure and specialized HVAC",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 11,
      "capability_name": "Mammalian Cell Culture (CHO/HEK293)",
      "capability_category": "Biologics Production",
      "approach_category": "Upstream",
      "description": "Large-scale mammalian cell culture expertise in stirred-tank bioreactors (2,000-20,000L) with process control, cell line management, and culture optimization for monoclonal antibody and protein production",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 12,
      "capability_name": "Microbial Fermentation",
      "capability_category": "Biologics Production",
      "approach_category": "Upstream",
      "description": "High-density bacterial fermentation (E. coli, yeast) for producing non-glycosylated proteins, enzymes, and peptides. Faster and more cost-effective than mammalian systems",
      "complexity_weight": 5,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 13,
      "capability_name": "Perfusion Culture Technology",
      "capability_category": "Biologics Production",
      "approach_category": "Upstream",
      "description": "Advanced continuous cell culture capability using ATF or TFF systems achieving high cell densities (>100 \u00d7 10\u2076 cells/mL) and improved volumetric productivity",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 14,
      "capability_name": "Cell Line Development & Engineering",
      "capability_category": "Biologics Production",
      "approach_category": "Upstream",
      "description": "Capability to develop stable, high-producing cell lines using traditional methods or CRISPR/Cas9 gene editing. Includes MCB/WCB generation and characterization under GMP",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 15,
      "capability_name": "Fed-Batch Culture Optimization",
      "capability_category": "Biologics Production",
      "approach_category": "Upstream",
      "description": "Expertise in optimizing fed-batch processes to achieve high titers (>10 g/L for mAbs) through media optimization, feeding strategies, and process intensification",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 16,
      "capability_name": "Multi-Step Chromatography Platform",
      "capability_category": "Purification",
      "approach_category": "Downstream",
      "description": "Integrated multi-modal chromatography capability including affinity (Protein A), ion exchange, hydrophobic interaction, and mixed-mode chromatography for biologics purification",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 17,
      "capability_name": "Continuous Chromatography",
      "capability_category": "Purification",
      "approach_category": "Downstream",
      "description": "Advanced continuous purification using SMB, multi-column, or periodic counter-current systems. Improves productivity and reduces buffer consumption versus batch chromatography",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 18,
      "capability_name": "Protein A Purification",
      "capability_category": "Purification",
      "approach_category": "Downstream",
      "description": "Industry-standard affinity capture for antibodies using Protein A chromatography. Single-step achieves 90-95% purity with high selectivity for immunoglobulin Fc region",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 19,
      "capability_name": "Viral Clearance & Safety",
      "capability_category": "Purification",
      "approach_category": "Downstream",
      "description": "Validated viral inactivation and removal capability including low pH treatment, solvent/detergent, and nanofiltration (20nm) demonstrating >4 log reduction for patient safety",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 20,
      "capability_name": "Ultra-High Purity Purification",
      "capability_category": "Purification",
      "approach_category": "Downstream",
      "description": "Capability to achieve >99% purity with tight control of aggregates, fragments, and variants. Essential for biologics and sensitive small molecules requiring exceptional purity",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 21,
      "capability_name": "Crystallization & Polymorphism Control",
      "capability_category": "Chemical Manufacturing",
      "approach_category": "Downstream",
      "description": "Controlled crystallization capability ensuring target polymorphic form and particle size distribution. Uses PAT monitoring (FBRM, PVM) and seeding strategies for reproducible results",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 22,
      "capability_name": "Amorphous Solid Dispersion (ASD) Technology",
      "capability_category": "Formulation",
      "approach_category": "Drug Product",
      "description": "Capability to create stable amorphous solid dispersions via hot-melt extrusion or spray drying for poorly soluble compounds, enhancing bioavailability through molecular dispersion in polymer matrix",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 23,
      "capability_name": "Spray Drying Technology",
      "capability_category": "Process Technology",
      "approach_category": "Drug Product",
      "description": "Single-step drying and particle formation capability creating fine powders, ASDs, or inhalable particles with controlled size distribution through rapid solvent evaporation",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 24,
      "capability_name": "BSL-2+ Containment Facilities",
      "capability_category": "Safety & Containment",
      "approach_category": "Facility",
      "description": "Biosafety Level 2 (or higher) facilities with negative pressure, HEPA filtration, and appropriate PPE for handling live viral vectors, genetically modified organisms, and infectious materials",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 25,
      "capability_name": "Viral Vector Manufacturing",
      "capability_category": "Advanced Therapies",
      "approach_category": "Upstream",
      "description": "Production capability for AAV, lentivirus, or adenovirus vectors using transient transfection or baculovirus systems. Requires BSL-2+ containment and specialized purification for empty/full capsid separation",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 26,
      "capability_name": "Lentiviral Vector Production",
      "capability_category": "Advanced Therapies",
      "approach_category": "Upstream",
      "description": "Multi-plasmid transient transfection capability for lentiviral vector production used in CAR-T manufacturing. Requires BSL-2+ containment and achieves 10\u2076-10\u2077 TU/mL titers",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 27,
      "capability_name": "AAV Vector Production",
      "capability_category": "Advanced Therapies",
      "approach_category": "Upstream",
      "description": "Capability for AAV production using triple-plasmid HEK293 transfection or baculovirus-Sf9 systems. Latter provides 10-100x higher yields enabling commercial-scale gene therapy manufacturing",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 28,
      "capability_name": "Empty/Full Capsid Separation",
      "capability_category": "Advanced Therapies",
      "approach_category": "Downstream",
      "description": "Specialized purification capability separating functional (full) AAV capsids from empty capsids using advanced chromatography or ultracentrifugation. Critical quality attribute for gene therapies",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 29,
      "capability_name": "Autologous Cell Processing",
      "capability_category": "Advanced Therapies",
      "approach_category": "Cell Therapy",
      "description": "Patient-specific cell isolation, modification, and expansion with rigorous chain-of-identity tracking from leukapheresis through manufacturing to re-infusion. Requires specialized logistics and quality systems",
      "complexity_weight": 10,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 30,
      "capability_name": "Allogeneic Cell Manufacturing",
      "capability_category": "Advanced Therapies",
      "approach_category": "Cell Therapy",
      "description": "Production of off-the-shelf cell therapies from healthy donor master cell banks. Requires CRISPR editing to prevent rejection and enables scalable batch manufacturing versus autologous approach",
      "complexity_weight": 10,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 31,
      "capability_name": "Ex-Vivo Cell Expansion",
      "capability_category": "Advanced Therapies",
      "approach_category": "Cell Therapy",
      "description": "7-14 day expansion of genetically modified T-cells using activation beads, cytokines, and controlled culture to generate therapeutic doses (10\u2078-10\u2079 cells) for CAR-T products",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 32,
      "capability_name": "Genetic Modification (Viral Transduction)",
      "capability_category": "Advanced Therapies",
      "approach_category": "Cell Therapy",
      "description": "Capability to genetically modify primary cells via lentiviral or retroviral transduction for CAR-T and TCR-T therapies. Requires optimization of transduction efficiency and vector copy number",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 33,
      "capability_name": "Cell Cryopreservation",
      "capability_category": "Advanced Therapies",
      "approach_category": "Cell Therapy",
      "description": "Controlled-rate freezing capability using DMSO-based formulations and programmable freezers to preserve cell viability during storage (-150\u00b0C to -196\u00b0C) and transport for cell therapy products",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 34,
      "capability_name": "Vein-to-Vein Logistics",
      "capability_category": "Advanced Therapies",
      "approach_category": "Cell Therapy",
      "description": "End-to-end coordination of autologous cell therapy from patient leukapheresis through manufacturing to re-infusion. Requires sophisticated tracking, quality systems, and cold chain management (current: 3-5 weeks)",
      "complexity_weight": 10,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 35,
      "capability_name": "Lipid Nanoparticle (LNP) Formulation",
      "capability_category": "Advanced Therapies",
      "approach_category": "Formulation",
      "description": "Microfluidic assembly of nucleic acid-lipid nanoparticles for mRNA/siRNA delivery. Requires precise control to achieve 75\u00b125nm particle size, <0.1 PDI, and >90% encapsulation efficiency",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 36,
      "capability_name": "Nucleic Acid Manufacturing",
      "capability_category": "Advanced Therapies",
      "approach_category": "Upstream",
      "description": "Production capability for oligonucleotides, siRNA, or mRNA including solid-phase synthesis (oligos), in-vitro transcription (mRNA), and purification achieving >85-90% main peak purity",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 37,
      "capability_name": "Antibody-Drug Conjugation (ADC)",
      "capability_category": "Biologics Production",
      "approach_category": "Downstream",
      "description": "Chemical conjugation of cytotoxic payloads to antibodies via lysine/cysteine or site-specific methods. Requires high-potency containment and post-conjugation purification to achieve target DAR (2-4)",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 38,
      "capability_name": "Site-Specific Conjugation",
      "capability_category": "Biologics Production",
      "approach_category": "Downstream",
      "description": "Advanced conjugation using engineered cysteines, unnatural amino acids, or enzymatic methods for homogeneous ADCs with improved therapeutic index versus random conjugation",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 39,
      "capability_name": "Biologics Formulation Development",
      "capability_category": "Formulation",
      "approach_category": "Drug Product",
      "description": "Expertise in formulating stable protein therapeutics including buffer selection (histidine, citrate), stabilizers (sucrose, trehalose), and surfactants (polysorbate). Optimizes pH, osmolality, and ionic strength",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 40,
      "capability_name": "Poorly Soluble Compound Formulation",
      "capability_category": "Formulation",
      "approach_category": "Drug Product",
      "description": "Specialized formulation approaches for BCS Class II/IV compounds including lipid-based systems, self-emulsifying formulations, and nanotechnology to enhance bioavailability",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 41,
      "capability_name": "Controlled Release Technology",
      "capability_category": "Formulation",
      "approach_category": "Drug Product",
      "description": "Capability to develop modified-release dosage forms including extended-release, delayed-release, and pulsatile delivery systems using polymer coatings, matrix systems, or specialized excipients",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 42,
      "capability_name": "Aseptic Fill-Finish (Biologics)",
      "capability_category": "Drug Product",
      "approach_category": "Fill-Finish",
      "description": "Class A/B cleanroom operations for sterile filling of vials, syringes, or cartridges with aseptic technique, environmental monitoring, and container closure integrity. Critical for injectable biologics",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 43,
      "capability_name": "Lyophilization (Freeze-Drying)",
      "capability_category": "Drug Product",
      "approach_category": "Fill-Finish",
      "description": "Controlled freeze-drying capability with cycle development (freezing, primary/secondary drying) to create stable powder formulations achieving <3% residual moisture. Extends biologics shelf-life",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 44,
      "capability_name": "Pre-Filled Syringe Manufacturing",
      "capability_category": "Drug Product",
      "approach_category": "Fill-Finish",
      "description": "Direct filling into syringes with specialized equipment handling siliconized syringes, plungers, and tip caps. Improves dosing accuracy and patient convenience for biologics",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 45,
      "capability_name": "Auto-Injector Device Integration",
      "capability_category": "Drug Product",
      "approach_category": "Fill-Finish",
      "description": "Integration of drug product with delivery devices (auto-injectors, pen injectors) requiring device assembly, functionality testing, and human factors validation for self-administration",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 46,
      "capability_name": "Continuous Manufacturing (Pharma)",
      "capability_category": "Process Technology",
      "approach_category": "Advanced",
      "description": "End-to-end continuous processing from API synthesis through final dosage form. Requires real-time monitoring, material traceability, residence time modeling, and control strategies per ICH Q13",
      "complexity_weight": 9,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 47,
      "capability_name": "Twin Screw Granulation (TSG)",
      "capability_category": "Process Technology",
      "approach_category": "Drug Product",
      "description": "Continuous wet granulation using twin-screw extruders enabling consistent particle formation and integration into continuous tablet manufacturing lines. Superior content uniformity versus batch",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 48,
      "capability_name": "Direct Compression",
      "capability_category": "Drug Product",
      "approach_category": "Fill-Finish",
      "description": "Single-step tablet manufacturing mixing API and excipients followed directly by compression. Simplest approach when material properties allow, reducing processing steps and cost",
      "complexity_weight": 3,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 49,
      "capability_name": "Tablet Coating Technology",
      "capability_category": "Drug Product",
      "approach_category": "Fill-Finish",
      "description": "Application of functional (enteric, sustained-release) or aesthetic coatings using pan coating or fluid bed systems. Controls drug release and improves product appearance/stability",
      "complexity_weight": 5,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 50,
      "capability_name": "Single-Use Systems",
      "capability_category": "Process Technology",
      "approach_category": "Advanced",
      "description": "Capability to utilize pre-sterilized disposable bioreactors, mixers, and transfer systems eliminating cleaning validation and cross-contamination risks. Standard for clinical/commercial biologics",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 51,
      "capability_name": "Isolator Technology",
      "capability_category": "Safety & Containment",
      "approach_category": "Facility",
      "description": "Grade A isolators with HEPA filtration providing superior sterility assurance for aseptic processing or high-potency compound handling. Reduces human intervention risk",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 52,
      "capability_name": "Cold Chain Management",
      "capability_category": "Logistics",
      "approach_category": "Distribution",
      "description": "Unbroken cold chain capability (2-8\u00b0C or frozen) with qualified shipping containers, continuous temperature monitoring, and validated shipping lanes for biologics and mRNA products",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 53,
      "capability_name": "Cryogenic Storage & Handling",
      "capability_category": "Logistics",
      "approach_category": "Distribution",
      "description": "Ultra-cold storage and handling capability (-70\u00b0C to -196\u00b0C) using liquid nitrogen dewars or ultra-low freezers. Required for mRNA vaccines, viral vectors, and cell therapies",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 54,
      "capability_name": "Serialization & Track-Trace",
      "capability_category": "Process Technology",
      "approach_category": "Advanced",
      "description": "Implementation of unit-level unique identifiers and aggregation per DSCSA/EU FMD requirements for supply chain security and anti-counterfeiting compliance",
      "complexity_weight": 5,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 55,
      "capability_name": "Quality by Design (QbD)",
      "capability_category": "Process Development",
      "approach_category": "Quality Systems",
      "description": "Systematic QbD approach with QTPP definition, CQA/CPP identification, Design of Experiments, design space establishment, and control strategy development per ICH Q8/Q9/Q10",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 56,
      "capability_name": "Process Analytical Technology (PAT)",
      "capability_category": "Process Development",
      "approach_category": "Quality Systems",
      "description": "Real-time process monitoring and control using NIR, Raman spectroscopy, FBRM, or other in-line/on-line analytics enabling proactive quality management and RTRT",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 57,
      "capability_name": "Design of Experiments (DoE)",
      "capability_category": "Process Development",
      "approach_category": "Quality Systems",
      "description": "Statistical experimental design capability using factorial or response surface methods to understand parameter-attribute relationships and establish science-based design space",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 58,
      "capability_name": "Scale-Up & Technology Transfer",
      "capability_category": "Process Development",
      "approach_category": "Quality Systems",
      "description": "Capability to progress from pilot to commercial scale (e.g., 200L to 20,000L) with comprehensive documentation, cross-functional teams, and validation demonstrating comparability",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 59,
      "capability_name": "Advanced Analytical Methods",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "Sophisticated characterization capability including mass spectrometry, Multi-Attribute Methods (MAM), higher-order structure analysis, and impurity profiling validated per ICH Q2(R2)/Q14",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 60,
      "capability_name": "Mass Spectrometry (Protein Characterization)",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "High-resolution MS capability for comprehensive biologics characterization including sequence variants, PTMs, glycosylation, and host cell protein analysis",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 61,
      "capability_name": "Real-Time Release Testing (RTRT)",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "Advanced PAT application verifying product quality through process data rather than end-product testing. Significantly reduces cycle times with appropriate validation",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 62,
      "capability_name": "Stability & Comparability Studies",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "ICH-compliant stability programs and comparability assessment capability demonstrating manufacturing changes don't adversely impact quality using risk-based approaches",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 63,
      "capability_name": "Current Good Manufacturing Practice (cGMP)",
      "capability_category": "Regulatory Compliance",
      "approach_category": "Quality Systems",
      "description": "Comprehensive GMP systems covering facility design, equipment qualification, personnel training, documentation, batch records, change control, deviation management, and CAPA",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 64,
      "capability_name": "Regulatory CMC Submissions",
      "capability_category": "Regulatory Compliance",
      "approach_category": "Quality Systems",
      "description": "Capability to prepare comprehensive Chemistry, Manufacturing, and Controls documentation for regulatory submissions (IND, NDA, BLA, MAA) in eCTD format for global agencies",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 65,
      "capability_name": "Regulatory Inspection Readiness",
      "capability_category": "Regulatory Compliance",
      "approach_category": "Quality Systems",
      "description": "Systems ensuring continuous inspection readiness including mock audits, compliance monitoring, rapid CAPA for observations, and maintaining robust quality management systems",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 66,
      "capability_name": "ICH Guideline Implementation",
      "capability_category": "Regulatory Compliance",
      "approach_category": "Quality Systems",
      "description": "Implementation of harmonized international standards (ICH Q7, Q8-Q14, Q2(R2)) enabling consistent requirements across regions and streamlined global development",
      "complexity_weight": 5,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 67,
      "capability_name": "Process Validation",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "Risk-based validation approach including prospective, concurrent, and continued process verification demonstrating consistent manufacturing of quality products per regulatory requirements",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 68,
      "capability_name": "Cleaning Validation",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "Validated cleaning procedures and analytical methods demonstrating adequate removal of product residues, cleaning agents, and microbial contamination between campaigns",
      "complexity_weight": 5,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 69,
      "capability_name": "Environmental Monitoring (Cleanroom)",
      "capability_category": "Quality Control",
      "approach_category": "Quality Systems",
      "description": "Comprehensive monitoring of viable/non-viable particles, temperature, humidity, and differential pressure in classified environments ensuring aseptic processing conditions",
      "complexity_weight": 5,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 70,
      "capability_name": "Supply Chain Risk Management",
      "capability_category": "Process Development",
      "approach_category": "Quality Systems",
      "description": "Systematic supply chain mapping, supplier qualification, dual-sourcing strategies, and AI-powered risk monitoring to mitigate geopolitical risks and ensure material availability",
      "complexity_weight": 6,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 71,
      "capability_name": "Digital Manufacturing & Industry 4.0",
      "capability_category": "Process Technology",
      "approach_category": "Advanced",
      "description": "Digital transformation capability including process simulation, digital twins, predictive maintenance, and data analytics for continuous improvement and optimization",
      "complexity_weight": 8,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    },
    {
      "capability_id": 72,
      "capability_name": "Biosafety & Biosecurity",
      "capability_category": "Safety & Containment",
      "approach_category": "Facility",
      "description": "Comprehensive biosafety programs including facility design, SOPs, training, waste management, and incident response for handling biological materials and GMOs",
      "complexity_weight": 7,
      "created_at": "2025-09-22T14:44:35.833026+00:00"
    }
  ],
  "manufacturing_entities": [],
  "internal_facilities": [],
  "external_partners": [],
  "process_templates": [
    {
      "template_id": 2,
      "modality_id": 10,
      "template_name": "Standard Bacteria Process",
      "description": "A specialized process for live bacterial products, involving fermentation, recovery, and lyophilization to ensure viability.",
      "created_at": "2025-09-25T16:57:12.393383+00:00"
    },
    {
      "template_id": 3,
      "modality_id": 15,
      "template_name": "Standard Base/Prime Editing Process",
      "description": "Manufacturing of components for in-vivo gene editing, involving mRNA/gRNA synthesis and formulation into a lipid nanoparticle (LNP) delivery system.",
      "created_at": "2025-09-25T16:57:12.407229+00:00"
    },
    {
      "template_id": 4,
      "modality_id": 12,
      "template_name": "Standard CAR-NK Process",
      "description": "A cell therapy process for engineering Natural Killer (NK) cells, with potential for allogeneic 'off-the-shelf' approaches.",
      "created_at": "2025-09-25T16:57:12.418129+00:00"
    },
    {
      "template_id": 5,
      "modality_id": 8,
      "template_name": "Standard CAR-T Process",
      "description": "A personalized 'vein-to-vein' manufacturing process involving patient cell collection, genetic modification, cell expansion, and cryogenic preservation.",
      "created_at": "2025-09-25T16:57:12.433177+00:00"
    },
    {
      "template_id": 6,
      "modality_id": 9,
      "template_name": "Standard Gene Therapy Process",
      "description": "Production of viral vectors (e.g., AAV) for gene delivery, involving cell culture, transfection, purification to isolate functional vectors, and aseptic filling.",
      "created_at": "2025-09-25T16:57:12.444320+00:00"
    },
    {
      "template_id": 7,
      "modality_id": 16,
      "template_name": "Standard Molecular Glues Process",
      "description": "A process for novel small molecule protein degraders, requiring specialized synthesis and formulation development.",
      "created_at": "2025-09-25T16:57:12.455957+00:00"
    },
    {
      "template_id": 8,
      "modality_id": 2,
      "template_name": "Standard Monoclonal Antibody Process",
      "description": "A typical biologics process for producing monoclonal antibodies using mammalian cell culture, followed by purification and aseptic filling.",
      "created_at": "2025-09-25T16:57:12.466049+00:00"
    },
    {
      "template_id": 9,
      "modality_id": 11,
      "template_name": "Standard Oligonucleotides Process",
      "description": "A process centered on solid-phase synthesis of nucleic acids, followed by extensive purification, formulation, and aseptic filling.",
      "created_at": "2025-09-25T16:57:12.477733+00:00"
    },
    {
      "template_id": 10,
      "modality_id": 7,
      "template_name": "Standard PROTAC Process",
      "description": "Manufacturing of complex, high molecular weight small molecules involving multi-step synthesis and advanced formulation to address bioavailability challenges.",
      "created_at": "2025-09-25T16:57:12.487348+00:00"
    },
    {
      "template_id": 11,
      "modality_id": 3,
      "template_name": "Standard Peptides Process",
      "description": "A process based on solid-phase peptide synthesis (SPPS), followed by cleavage, purification, and sterile product formulation, often including device integration.",
      "created_at": "2025-09-25T16:57:12.497081+00:00"
    },
    {
      "template_id": 12,
      "modality_id": 19,
      "template_name": "Standard Prescription Digital Therapeutic (SaMD/PDT) Process",
      "description": "A regulated software development lifecycle (SDLC) process for creating, validating, and deploying software as a medical device.",
      "created_at": "2025-09-25T16:57:12.507772+00:00"
    },
    {
      "template_id": 13,
      "modality_id": 17,
      "template_name": "Standard Radiopharmaceuticals Process",
      "description": "A time-critical process involving radioisotope production, rapid synthesis and purification, and just-in-time distribution due to short half-life.",
      "created_at": "2025-09-25T16:57:12.518395+00:00"
    },
    {
      "template_id": 14,
      "modality_id": 6,
      "template_name": "Standard Recombinant Proteins Process",
      "description": "Manufacturing process for engineered proteins, involving cell culture, complex purification, and sterile formulation.",
      "created_at": "2025-09-25T16:57:12.528281+00:00"
    },
    {
      "template_id": 15,
      "modality_id": 1,
      "template_name": "Standard Small Molecule Process",
      "description": "A standard process for chemically synthesized active pharmaceutical ingredients (APIs) formulated into an oral solid dosage form.",
      "created_at": "2025-09-25T16:57:12.539193+00:00"
    },
    {
      "template_id": 16,
      "modality_id": 18,
      "template_name": "Standard Stem Cell Therapies Process",
      "description": "A process for expanding and differentiating stem cells for therapeutic use, which can be either autologous or allogeneic.",
      "created_at": "2025-09-25T16:57:12.548830+00:00"
    },
    {
      "template_id": 17,
      "modality_id": 4,
      "template_name": "Standard T-cell Engager Process",
      "description": "A complex biologics process for bispecific antibodies, requiring advanced protein engineering, controlled expression, and sophisticated purification.",
      "created_at": "2025-09-25T16:57:12.560827+00:00"
    },
    {
      "template_id": 18,
      "modality_id": 13,
      "template_name": "Standard TCR-T Process",
      "description": "A personalized T-cell therapy process involving TCR gene modification, cell expansion, and cryopreservation for solid tumor applications.",
      "created_at": "2025-09-25T16:57:12.573767+00:00"
    },
    {
      "template_id": 19,
      "modality_id": 14,
      "template_name": "Standard Trispecific Antibodies Process",
      "description": "A highly complex process for multi-specific antibodies, with critical controls on chain pairing, purity, and aggregation.",
      "created_at": "2025-09-25T16:57:12.584288+00:00"
    }
  ],
  "products": [
    {
      "product_id": 9,
      "product_code": "BI 1810631",
      "product_name": "Zongertinib",
      "product_type": "NME",
      "short_description": "HER2-selective TKI for NSCLC and other HER2-driven cancers",
      "description": "Zongertinib is an oral, irreversible HER2-selective TKI targeting HER2 gene alterations across multiple tumor types. It is being developed for NSCLC and other HER2-driven cancers.",
      "base_technology": "Organic Spray Drying; Roller Compaction",
      "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI)",
      "dosage_form": "Tablet",
      "therapeutic_area": "Oncology",
      "current_phase": "Registration",
      "project_status": "On Track",
      "lead_indication": "NSCLC (2nd Line)",
      "expected_launch_year": 2025,
      "lifecycle_indications": null,
      "regulatory_designations": null,
      "manufacturing_strategy": null,
      "manufacturing_sites": null,
      "volume_forecast": null,
      "modality_id": 1,
      "primary_packaging": "Bottle",
      "route_of_administration": "Oral",
      "biel_category": "3A",
      "granulation_technology": null,
      "submission_status": "Submitted",
      "submission_date": null,
      "approval_date": null,
      "launch_geography": "US",
      "regulatory_details": {
        "NSCLC_2L": [
          "Breakthrough Therapy",
          "Fast Track"
        ]
      },
      "ppq_status": "Completed",
      "ppq_completion_date": null,
      "ppq_details": {
        "DP": {
          "ING": "launch_ready",
          "Hovione": "completed"
        },
        "DS": {
          "Alphora": "backup_qualified",
          "Cambrex": "completed"
        }
      },
      "timeline_variance_days": 0,
      "timeline_variance_baseline": "AD 2024",
      "critical_path_item": "OPS",
      "ds_volume_category": "Low (10-1,000 kg)",
      "dp_volume_category": "Low (1-10 million PCS)",
      "ds_suppliers": [
        {
          "name": "Cambrex",
          "role": "Primary",
          "site": "N/A",
          "status": "qualified"
        },
        {
          "name": "Alphora",
          "role": "Backup",
          "site": "N/A",
          "status": "qualified"
        }
      ],
      "dp_suppliers": [
        {
          "name": "Hovione",
          "role": "Launch",
          "site": "Portugal",
          "status": "launch_ready"
        },
        {
          "name": "ING",
          "role": "Launch",
          "site": "Ingelheim",
          "status": "launch_ready"
        }
      ],
      "device_partners": null,
      "operational_risks": {
        "high": [
          "If something goes wrong, impact on submission/launch timepoint highly likely"
        ]
      },
      "timeline_risks": {
        "critical": [
          "Slight shift due to clinical activities"
        ]
      },
      "supply_chain_risks": null,
      "clinical_trials": {
        "phase_1": {
          "status": "Ongoing",
          "indication": "HER2-driven cancers",
          "trial_name": "NCT04886804"
        }
      },
      "patient_population": "Advanced NSCLC patients with HER2 mutations",
      "development_program_name": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": "2025-09-24T17:19:30.836942+00:00"
    },
    {
      "product_id": 10,
      "product_code": "BI 1015550",
      "product_name": "Nerandomilast",
      "product_type": "NME",
      "short_description": "First-in-class PDE4B inhibitor for pulmonary fibrosis",
      "description": "Nerandomilast is an oral PDE4B inhibitor developed to potentially stop disease progression in idiopathic pulmonary fibrosis. It is part of the global FIBRONEER\u2122 Phase III program.",
      "base_technology": "Twin Screw",
      "mechanism_of_action": "Preferential PDE4B inhibitor",
      "dosage_form": "Tablet",
      "therapeutic_area": "Respiratory",
      "current_phase": "Registration",
      "project_status": "On Track",
      "lead_indication": "Idiopathic Pulmonary Fibrosis (IPF)",
      "expected_launch_year": 2025,
      "lifecycle_indications": null,
      "regulatory_designations": null,
      "manufacturing_strategy": null,
      "manufacturing_sites": null,
      "volume_forecast": null,
      "modality_id": 1,
      "primary_packaging": "Blister; Bottle",
      "route_of_administration": "Oral",
      "biel_category": "3A",
      "granulation_technology": null,
      "submission_status": "Submitted",
      "submission_date": null,
      "approval_date": null,
      "launch_geography": "Global",
      "regulatory_details": {
        "IPF": [
          "Breakthrough Therapy",
          "Orphan Drug"
        ]
      },
      "ppq_status": "Completed",
      "ppq_completion_date": null,
      "ppq_details": {
        "DP": {
          "ING_SoL": "completed"
        },
        "DS": {
          "ING": "completed"
        }
      },
      "timeline_variance_days": -10,
      "timeline_variance_baseline": "AD 2024",
      "critical_path_item": "Regulatory",
      "ds_volume_category": "Low (10-1,000 kg)",
      "dp_volume_category": "Medium (10-100 million PCS)",
      "ds_suppliers": [
        {
          "name": "ING",
          "role": "Primary",
          "site": "Ingelheim",
          "status": "qualified"
        }
      ],
      "dp_suppliers": [
        {
          "name": "ING_SoL",
          "role": "Launch",
          "site": "Ingelheim",
          "status": "qualified"
        }
      ],
      "device_partners": null,
      "operational_risks": {
        "high": [
          "Formulation risk due to TiO2 bridging requirement"
        ]
      },
      "timeline_risks": {
        "critical": [
          "Potential delay due to BE study requirement"
        ]
      },
      "supply_chain_risks": null,
      "clinical_trials": {
        "phase_3": {
          "status": "Ongoing",
          "indication": "IPF",
          "trial_name": "FIBRONEER\u2122"
        }
      },
      "patient_population": "Patients with IPF",
      "development_program_name": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": "2025-09-24T17:19:30.836942+00:00"
    },
    {
      "product_id": 11,
      "product_code": "BI 456906",
      "product_name": "Survodutide",
      "product_type": "NME",
      "short_description": "Injectable dual agonist for obesity and MASH",
      "description": "Survodutide is a novel injectable dual agonist targeting GLP-1 and glucagon receptors, developed for obesity and MASH. It is derived from oxyntomodulin and delivered via a PEN device.",
      "base_technology": "Single-use isolator",
      "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase III",
      "project_status": "Delayed",
      "lead_indication": "Obesity",
      "expected_launch_year": 2027,
      "lifecycle_indications": null,
      "regulatory_designations": null,
      "manufacturing_strategy": null,
      "manufacturing_sites": null,
      "volume_forecast": null,
      "modality_id": 3,
      "primary_packaging": null,
      "route_of_administration": "Injectable",
      "biel_category": null,
      "granulation_technology": null,
      "submission_status": "In Progress",
      "submission_date": null,
      "approval_date": null,
      "launch_geography": "Global",
      "regulatory_details": {
        "Obesity": [
          "Breakthrough Therapy",
          "Fast Track"
        ]
      },
      "ppq_status": "At Risk",
      "ppq_completion_date": null,
      "ppq_details": {
        "DP": {
          "Nemera": "device ramp-up",
          "Thermo Fisher": "ongoing"
        },
        "DS": {
          "PPG": "halted"
        }
      },
      "timeline_variance_days": 86,
      "timeline_variance_baseline": "AD 2024",
      "critical_path_item": "CMC",
      "ds_volume_category": null,
      "dp_volume_category": null,
      "ds_suppliers": [
        {
          "name": "PPG",
          "role": "Primary",
          "site": "N/A",
          "status": "halted"
        }
      ],
      "dp_suppliers": [
        {
          "name": "Thermo Fisher",
          "role": "Manufacturing",
          "site": "N/A",
          "status": "ongoing"
        },
        {
          "name": "Nemera",
          "role": "Device",
          "site": "N/A",
          "status": "ramp-up"
        }
      ],
      "device_partners": [
        {
          "name": "Nemera",
          "role": "Primary",
          "device_type": "PEN"
        }
      ],
      "operational_risks": {
        "high": [
          "DS PPQ halted",
          "High-risk formulation 2.0 development"
        ]
      },
      "timeline_risks": {
        "critical": [
          "+86 day delay for Obesity",
          "+91 day delay for MASH"
        ]
      },
      "supply_chain_risks": null,
      "clinical_trials": {
        "phase_3": {
          "status": "Ongoing",
          "indication": "Obesity",
          "trial_name": "Survodutide Obesity Trial"
        }
      },
      "patient_population": "Adults with BMI \u2265 27 kg/m\u00b2",
      "development_program_name": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": "2025-09-24T17:19:30.836942+00:00"
    },
    {
      "product_id": 12,
      "product_code": "BI 690517",
      "product_name": "Vicadrostat",
      "product_type": "NME",
      "short_description": "ASi developed in combination with empagliflozin for CKD and HFpEF",
      "description": "Vicadrostat is a selective aldosterone synthase inhibitor developed in combination with empagliflozin for CKD and HFpEF. It aims to reduce aldosterone-driven disease progression.",
      "base_technology": "Twin Screw",
      "mechanism_of_action": "Selective aldosterone synthase inhibitor",
      "dosage_form": "Tablet",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase III",
      "project_status": "On Track",
      "lead_indication": "Chronic Kidney Disease (CKD)",
      "expected_launch_year": 2028,
      "lifecycle_indications": null,
      "regulatory_designations": null,
      "manufacturing_strategy": null,
      "manufacturing_sites": null,
      "volume_forecast": null,
      "modality_id": 1,
      "primary_packaging": "Blister; Bottle",
      "route_of_administration": "Oral",
      "biel_category": "3A",
      "granulation_technology": null,
      "submission_status": "Not Started",
      "submission_date": null,
      "approval_date": null,
      "launch_geography": "Global",
      "regulatory_details": null,
      "ppq_status": "Ongoing",
      "ppq_completion_date": null,
      "ppq_details": {
        "DP": {
          "ING_SoL": "transfer ongoing"
        },
        "DS": {
          "ING": "transfer ongoing"
        }
      },
      "timeline_variance_days": 0,
      "timeline_variance_baseline": "AD 2024",
      "critical_path_item": "Operations",
      "ds_volume_category": "High (>10 tn)",
      "dp_volume_category": "High (>100 million PCS)",
      "ds_suppliers": [
        {
          "name": "ING",
          "role": "Primary",
          "site": "Ingelheim",
          "status": "transfer ongoing"
        }
      ],
      "dp_suppliers": [
        {
          "name": "ING_SoL",
          "role": "Primary",
          "site": "Ingelheim",
          "status": "transfer ongoing"
        }
      ],
      "device_partners": null,
      "operational_risks": null,
      "timeline_risks": null,
      "supply_chain_risks": null,
      "clinical_trials": {
        "phase_3": {
          "status": "Ongoing",
          "indication": "CKD",
          "trial_name": "Vicadrostat CKD Trial"
        }
      },
      "patient_population": "Patients with CKD and HFpEF",
      "development_program_name": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": "2025-09-24T17:19:30.836942+00:00"
    }
  ],
  "indications": [],
  "manufacturing_technologies": [
    {
      "technology_id": 1,
      "technology_name": "Multi-Step Organic Synthesis",
      "short_description": "Complex chemical transformations for small molecule APIs",
      "description": "Advanced multi-step organic chemistry including asymmetric synthesis, transition metal-catalyzed reactions, heterocyclic chemistry, and protection/deprotection strategies. Essential for building complex small molecule structures.",
      "stage_id": 13,
      "innovation_potential": "Moderate - established chemistry with continuous refinement",
      "complexity_rating": 7
    },
    {
      "technology_id": 2,
      "technology_name": "Continuous Flow Chemistry",
      "short_description": "Continuous chemical synthesis in microreactors",
      "description": "Advanced continuous processing enabling better temperature control (\u00b12\u00b0C), faster reaction times, improved safety, and consistent product quality. Replaces traditional batch chemistry for small molecule synthesis.",
      "stage_id": 13,
      "innovation_potential": "High - transforming traditional batch paradigm",
      "complexity_rating": 8
    },
    {
      "technology_id": 3,
      "technology_name": "Cryogenic Reaction Technology",
      "short_description": "Ultra-low temperature reaction control",
      "description": "Specialized capability for conducting reactions at extremely low temperatures (down to -78\u00b0C or lower) with precise control. Required for certain sensitive transformations and highly reactive intermediates.",
      "stage_id": 13,
      "innovation_potential": "Low - specialized but established",
      "complexity_rating": 7
    },
    {
      "technology_id": 4,
      "technology_name": "PROTAC Synthesis Platform",
      "short_description": "24+ step synthesis for targeted protein degraders",
      "description": "Complex synthesis platform for PROTACs (>900 Da, three-component structure) requiring advanced linker chemistry, click chemistry, and SuFEx reactions. Significantly more complex than traditional small molecules with 24+ synthetic steps.",
      "stage_id": 13,
      "innovation_potential": "High - novel therapeutic modality",
      "complexity_rating": 9
    },
    {
      "technology_id": 5,
      "technology_name": "Large-Scale Hydrogenation",
      "short_description": "High-pressure catalytic hydrogenation",
      "description": "Industrial-scale hydrogenation reactions using precious metal catalysts (Pd, Pt, Rh) under high pressure. Critical for reduction steps in API synthesis, requires specialized equipment and safety controls.",
      "stage_id": 13,
      "innovation_potential": "Low - mature technology",
      "complexity_rating": 6
    },
    {
      "technology_id": 6,
      "technology_name": "CHO Cell Culture Platform",
      "short_description": "Chinese Hamster Ovary cell-based mAb production",
      "description": "Industry standard for monoclonal antibody production using CHO cells in fed-batch culture. Operates in 2,000-20,000L stirred-tank bioreactors with 14-day culture achieving titers >10 g/L through process intensification.",
      "stage_id": 13,
      "innovation_potential": "Moderate - mature platform with incremental improvements",
      "complexity_rating": 7
    },
    {
      "technology_id": 7,
      "technology_name": "HEK293 Cell Culture System",
      "short_description": "Human embryonic kidney cell production system",
      "description": "Human cell line used primarily for viral vector production (AAV, adenovirus) and complex protein expression. Enables human-like post-translational modifications but requires more complex culture conditions than CHO.",
      "stage_id": 13,
      "innovation_potential": "Moderate - essential for viral vectors",
      "complexity_rating": 8
    },
    {
      "technology_id": 8,
      "technology_name": "Microbial Fermentation (E. coli)",
      "short_description": "Bacterial expression for simple proteins",
      "description": "High-density E. coli fermentation for producing non-glycosylated proteins, enzymes, and peptides. Faster and more cost-effective than mammalian systems but limited to simpler proteins without complex modifications.",
      "stage_id": 13,
      "innovation_potential": "Low - established technology",
      "complexity_rating": 5
    },
    {
      "technology_id": 9,
      "technology_name": "Perfusion Cell Culture",
      "short_description": "Continuous cell culture with media exchange",
      "description": "Advanced continuous upstream process using Alternating Tangential Flow (ATF) or similar systems. Achieves higher cell densities (>100 \u00d7 10\u2076 cells/mL) and improved volumetric productivity versus fed-batch culture.",
      "stage_id": 14,
      "innovation_potential": "High - enables continuous biologics manufacturing",
      "complexity_rating": 8
    },
    {
      "technology_id": 10,
      "technology_name": "CRISPR/Cas9 Cell Line Engineering",
      "short_description": "Rapid cell line development using gene editing",
      "description": "Modern gene editing approach enabling stable, high-producing cell line generation in 12 weeks versus 6-12 months with traditional methods. Allows precise genomic integration and knockout of undesired genes.",
      "stage_id": 15,
      "innovation_potential": "High - revolutionizing cell line development",
      "complexity_rating": 8
    },
    {
      "technology_id": 11,
      "technology_name": "Master Cell Bank (MCB) Generation",
      "short_description": "GMP cell bank establishment and qualification",
      "description": "Generation and qualification of Master and Working Cell Banks under GMP conditions. Includes extensive testing for identity, purity, stability, and absence of adventitious agents. Foundation for consistent biologics production.",
      "stage_id": 15,
      "innovation_potential": "Low - required regulatory step",
      "complexity_rating": 6
    },
    {
      "technology_id": 12,
      "technology_name": "Triple Plasmid Transfection (AAV)",
      "short_description": "Transient AAV vector production in HEK293",
      "description": "Standard method for AAV production using three plasmids (rep/cap, transgene, helper) transfected into HEK293 cells. Requires BSL-2+ containment. Scalability limitations drive exploration of baculovirus alternatives.",
      "stage_id": 13,
      "innovation_potential": "Moderate - established but scalability-limited",
      "complexity_rating": 9
    },
    {
      "technology_id": 13,
      "technology_name": "Baculovirus-Sf9 System (AAV)",
      "short_description": "Insect cell-based AAV production",
      "description": "Alternative AAV production platform using baculovirus-infected Sf9 insect cells. Provides 10-100-fold higher yields than HEK293 transfection. Enables commercial-scale manufacturing of gene therapies.",
      "stage_id": 13,
      "innovation_potential": "High - solving AAV scalability challenge",
      "complexity_rating": 8
    },
    {
      "technology_id": 14,
      "technology_name": "Lentiviral Vector Production",
      "short_description": "Four-plasmid lentivirus generation system",
      "description": "Multi-plasmid transient transfection in HEK293 cells for lentiviral vector production used in ex-vivo CAR-T manufacturing. Requires BSL-2+ containment and produces 10\u2076-10\u2077 TU/mL titers.",
      "stage_id": 13,
      "innovation_potential": "Moderate - critical for cell therapy but complex",
      "complexity_rating": 9
    },
    {
      "technology_id": 15,
      "technology_name": "Ex-Vivo T-Cell Expansion",
      "short_description": "Patient T-cell activation and proliferation",
      "description": "7-14 day expansion of genetically modified T-cells using activation beads, cytokines (IL-2, IL-7, IL-15), and controlled culture conditions. Critical for generating therapeutic cell doses (10\u2078-10\u2079 cells) for CAR-T products.",
      "stage_id": 13,
      "innovation_potential": "Moderate - required for autologous therapies",
      "complexity_rating": 9
    },
    {
      "technology_id": 16,
      "technology_name": "Allogeneic Cell Bank Manufacturing",
      "short_description": "Off-the-shelf cell therapy production",
      "description": "Production of master cell banks from healthy donor cells for allogeneic cell therapies. Enables scalable, batch manufacturing versus patient-specific processing. Requires additional gene edits (CRISPR) to prevent rejection.",
      "stage_id": 13,
      "innovation_potential": "High - solving scalability of cell therapy",
      "complexity_rating": 10
    },
    {
      "technology_id": 17,
      "technology_name": "High-Performance Liquid Chromatography (HPLC)",
      "short_description": "Standard small molecule purification",
      "description": "Workhorse purification technique for small molecules using various modes (reversed-phase, normal-phase, chiral). Achieves high resolution separation of APIs from impurities and isomers.",
      "stage_id": 17,
      "innovation_potential": "Low - established standard",
      "complexity_rating": 5
    },
    {
      "technology_id": 18,
      "technology_name": "Continuous Chromatography",
      "short_description": "Simulated moving bed and multi-column systems",
      "description": "Continuous purification via SMB (Simulated Moving Bed) or multi-column systems (periodic counter-current, MCSGP). Improves productivity and reduces buffer consumption versus batch chromatography.",
      "stage_id": 17,
      "innovation_potential": "High - significant process intensification",
      "complexity_rating": 8
    },
    {
      "technology_id": 19,
      "technology_name": "Crystallization & Polymorphism Control",
      "short_description": "Controlled crystallization for purity and form",
      "description": "Critical unit operation using controlled temperature, seeding, and solvent systems to achieve target purity and polymorphic form. Monitored by PAT tools (FBRM, PVM). Continuous crystallization provides superior control.",
      "stage_id": 17,
      "innovation_potential": "Moderate - continuous processing advances",
      "complexity_rating": 7
    },
    {
      "technology_id": 20,
      "technology_name": "Hot-Melt Extrusion (HME)",
      "short_description": "Amorphous solid dispersion technology",
      "description": "Thermal processing method for creating amorphous solid dispersions (ASDs) of poorly soluble APIs. Continuous process using twin-screw extruders to molecularly disperse drug in polymer matrix, enhancing bioavailability.",
      "stage_id": 17,
      "innovation_potential": "High - enabling poorly soluble compounds",
      "complexity_rating": 7
    },
    {
      "technology_id": 21,
      "technology_name": "Spray Drying",
      "short_description": "Rapid solvent removal and particle formation",
      "description": "Single-step drying process creating fine powders or ASDs through rapid solvent evaporation. Used for thermally sensitive compounds or creating inhalable particles with controlled size distribution.",
      "stage_id": 20,
      "innovation_potential": "Moderate - established with improvements",
      "complexity_rating": 6
    },
    {
      "technology_id": 22,
      "technology_name": "Depth Filtration",
      "short_description": "Cell and debris removal from harvest",
      "description": "Multi-layered filter media for removing cells, cell debris, and large particulates from bioreactor harvest. Achieves >95% product recovery with <10 NTU turbidity. Often combined with centrifugation for high cell density cultures.",
      "stage_id": 16,
      "innovation_potential": "Low - established technology",
      "complexity_rating": 5
    },
    {
      "technology_id": 23,
      "technology_name": "Tangential Flow Filtration (TFF)",
      "short_description": "Concentration and buffer exchange",
      "description": "Membrane-based concentration and diafiltration using crossflow to minimize fouling. Used for viral vector concentration, protein concentration, and buffer exchange. Single-use systems increasingly common.",
      "stage_id": 16,
      "innovation_potential": "Moderate - single-use advances",
      "complexity_rating": 6
    },
    {
      "technology_id": 24,
      "technology_name": "Protein A Affinity Chromatography",
      "short_description": "Industry-standard mAb capture step",
      "description": "High-specificity capture using immobilized Protein A ligand binding to antibody Fc region. Single step achieves 90-95% purity. Most expensive chromatography media but unmatched selectivity for antibodies.",
      "stage_id": 17,
      "innovation_potential": "Low - mature technology with cost pressures",
      "complexity_rating": 6
    },
    {
      "technology_id": 25,
      "technology_name": "Ion Exchange Chromatography (IEX)",
      "short_description": "Charge-based separation",
      "description": "Uses electrostatic interactions for purification. Cation (CEX) or anion (AEX) modes remove charge variants, aggregates, and process impurities. Often second step after Protein A for mAbs.",
      "stage_id": 17,
      "innovation_potential": "Low - standard platform step",
      "complexity_rating": 5
    },
    {
      "technology_id": 26,
      "technology_name": "Hydrophobic Interaction Chromatography (HIC)",
      "short_description": "Hydrophobicity-based polishing",
      "description": "Separation based on surface hydrophobicity. Excellent for removing aggregates and high molecular weight species. Uses decreasing salt gradients for elution.",
      "stage_id": 17,
      "innovation_potential": "Low - established polishing step",
      "complexity_rating": 5
    },
    {
      "technology_id": 27,
      "technology_name": "Mixed-Mode Chromatography",
      "short_description": "Multi-mechanism purification",
      "description": "Combines multiple interaction modes (ionic, hydrophobic, hydrogen bonding) in single resin. Provides orthogonal selectivity and can reduce number of purification steps. Increasingly popular for complex biologics.",
      "stage_id": 17,
      "innovation_potential": "Moderate - expanding applications",
      "complexity_rating": 6
    },
    {
      "technology_id": 28,
      "technology_name": "Size Exclusion Chromatography (SEC)",
      "short_description": "Size-based separation and desalting",
      "description": "Separates based on molecular size/hydrodynamic radius. Used for aggregate removal, viral vector purification, and buffer exchange. Also analytical method for determining aggregation levels.",
      "stage_id": 17,
      "innovation_potential": "Low - standard technique",
      "complexity_rating": 4
    },
    {
      "technology_id": 29,
      "technology_name": "Antibody-Drug Conjugation (ADC)",
      "short_description": "Cytotoxic payload attachment to mAbs",
      "description": "Chemical conjugation of highly potent cytotoxic drugs to antibodies via lysine or cysteine residues or site-specific methods. Requires high-potency containment. Post-conjugation purification achieves target DAR (Drug-to-Antibody Ratio) of 2-4.",
      "stage_id": 18,
      "innovation_potential": "High - expanding therapeutic window",
      "complexity_rating": 9
    },
    {
      "technology_id": 30,
      "technology_name": "Site-Specific Conjugation",
      "short_description": "Precise payload attachment chemistry",
      "description": "Advanced conjugation methods using engineered cysteines, unnatural amino acids, or enzymatic conjugation (transglutaminase) for homogeneous ADCs. Improves therapeutic index versus traditional random conjugation.",
      "stage_id": 18,
      "innovation_potential": "High - next-generation ADCs",
      "complexity_rating": 9
    },
    {
      "technology_id": 31,
      "technology_name": "PEGylation",
      "short_description": "Polyethylene glycol conjugation",
      "description": "Attachment of polyethylene glycol chains to proteins/peptides to increase half-life, reduce immunogenicity, and improve stability. Requires post-PEGylation purification to remove unreacted PEG and multi-PEGylated species.",
      "stage_id": 18,
      "innovation_potential": "Moderate - established for life-cycle management",
      "complexity_rating": 6
    },
    {
      "technology_id": 32,
      "technology_name": "Low pH Viral Inactivation",
      "short_description": "Acid treatment for enveloped virus inactivation",
      "description": "Industry standard viral safety step using pH 3.5-4.0 treatment for 60+ minutes to inactivate enveloped viruses. Must demonstrate >4 log reduction. Typically performed after Protein A capture for antibodies.",
      "stage_id": 19,
      "innovation_potential": "Low - required regulatory step",
      "complexity_rating": 4
    },
    {
      "technology_id": 33,
      "technology_name": "Nanofiltration (20nm)",
      "short_description": "Size-based removal of small viruses",
      "description": "Dedicated viral filtration step using 20nm pore size membranes to physically remove both enveloped and non-enveloped viruses. Must demonstrate >4 log reduction. Orthogonal mechanism to low pH inactivation.",
      "stage_id": 19,
      "innovation_potential": "Low - standard safety measure",
      "complexity_rating": 5
    },
    {
      "technology_id": 34,
      "technology_name": "Solvent/Detergent Treatment",
      "short_description": "Chemical viral inactivation",
      "description": "Treatment with organic solvent (tri-n-butyl phosphate) and detergent (Triton X-100 or Tween 80) to disrupt lipid envelopes of viruses. Must be followed by removal step (chromatography) to eliminate residual chemicals.",
      "stage_id": 19,
      "innovation_potential": "Low - established for plasma products",
      "complexity_rating": 5
    },
    {
      "technology_id": 35,
      "technology_name": "Ultracentrifugation (Viral Vectors)",
      "short_description": "Density gradient separation for AAV",
      "description": "CsCl or iodixanol gradient ultracentrifugation to separate full AAV capsids from empty capsids and impurities. Provides high-quality product but difficult to scale. Increasingly replaced by chromatography for commercial manufacturing.",
      "stage_id": 17,
      "innovation_potential": "Low - legacy technology for AAV",
      "complexity_rating": 7
    },
    {
      "technology_id": 36,
      "technology_name": "Twin Screw Granulation (TSG)",
      "short_description": "Continuous wet granulation process",
      "description": "Continuous granulation using twin-screw extruder enabling consistent particle formation, better content uniformity, and integration into end-to-end continuous manufacturing lines. Replaces traditional batch granulation.",
      "stage_id": 26,
      "innovation_potential": "High - enables continuous tablet manufacturing",
      "complexity_rating": 7
    },
    {
      "technology_id": 37,
      "technology_name": "Direct Compression",
      "short_description": "Single-step tablet manufacturing",
      "description": "Simplest tablet manufacturing approach mixing API and excipients followed directly by compression. Requires good flow and compaction properties. Preferred when feasible due to reduced processing steps.",
      "stage_id": 26,
      "innovation_potential": "Low - standard approach when suitable",
      "complexity_rating": 3
    },
    {
      "technology_id": 38,
      "technology_name": "Fluid Bed Coating",
      "short_description": "Tablet coating in fluidized bed",
      "description": "Application of functional (enteric, sustained-release) or aesthetic coatings to tablets/pellets in fluidized bed. Provides uniform coating and controlled release properties. Can be integrated into continuous lines.",
      "stage_id": 26,
      "innovation_potential": "Moderate - continuous integration",
      "complexity_rating": 5
    },
    {
      "technology_id": 39,
      "technology_name": "Isolator Technology (Aseptic)",
      "short_description": "Closed aseptic processing environment",
      "description": "Grade A isolators with HEPA filtration and continuous overpressure providing superior sterility assurance versus traditional cleanrooms. Enables aseptic operations with reduced intervention risk. Often integrated with RABS.",
      "stage_id": 27,
      "innovation_potential": "Moderate - improving sterility assurance",
      "complexity_rating": 7
    },
    {
      "technology_id": 40,
      "technology_name": "Single-Use Systems (Biologics)",
      "short_description": "Disposable bioprocess equipment",
      "description": "Pre-sterilized disposable bioreactors, mixers, filters, and transfer assemblies eliminating cleaning validation and cross-contamination risks. Enables faster changeovers and flexible manufacturing. Now standard for clinical and commercial biologics.",
      "stage_id": 27,
      "innovation_potential": "Moderate - now industry standard",
      "complexity_rating": 6
    },
    {
      "technology_id": 41,
      "technology_name": "Blow-Fill-Seal (BFS)",
      "short_description": "Integrated container forming and filling",
      "description": "Single automated process forming plastic container from resin, filling with sterile product, and sealing in continuous operation. Provides excellent sterility assurance and cost-effectiveness for high-volume liquid products.",
      "stage_id": 30,
      "innovation_potential": "Moderate - niche application expansion",
      "complexity_rating": 7
    },
    {
      "technology_id": 42,
      "technology_name": "Pre-Filled Syringe Technology",
      "short_description": "Ready-to-use injectable delivery",
      "description": "Direct filling into syringes with staked needles or luer-lock connections. Improves dosing accuracy, reduces preparation errors, and enhances patient convenience. Requires specialized filling equipment and syringes with appropriate coatings (siliconization).",
      "stage_id": 30,
      "innovation_potential": "Moderate - patient preference driving adoption",
      "complexity_rating": 6
    },
    {
      "technology_id": 43,
      "technology_name": "Lyophilization (Freeze-Drying)",
      "short_description": "Controlled freeze-drying for stability",
      "description": "Three-stage process (freezing, primary drying under vacuum, secondary drying) removing water while preserving protein structure. Achieves residual moisture <3%. Extends shelf-life and enables ambient storage for unstable biologics.",
      "stage_id": 31,
      "innovation_potential": "Low - established but essential",
      "complexity_rating": 7
    },
    {
      "technology_id": 44,
      "technology_name": "Controlled-Rate Freezing",
      "short_description": "Cryopreservation for cell therapies",
      "description": "Programmable freezing using controlled-rate freezers (typically -1\u00b0C/min) with DMSO-based cryoprotectant formulations. Critical for maintaining cell viability during storage and transport at -150\u00b0C to -196\u00b0C for CAR-T and cell therapy products.",
      "stage_id": 32,
      "innovation_potential": "Moderate - essential for cell therapy logistics",
      "complexity_rating": 7
    },
    {
      "technology_id": 45,
      "technology_name": "Auto-Injector Integration",
      "short_description": "Self-injection device assembly",
      "description": "Integration of pre-filled syringes into spring-loaded or electronic auto-injector devices. Requires device functionality testing, needle safety verification, and human factors validation. Improves patient compliance and self-administration.",
      "stage_id": 32,
      "innovation_potential": "Moderate - enhancing patient experience",
      "complexity_rating": 6
    },
    {
      "technology_id": 46,
      "technology_name": "Lipid Nanoparticle (LNP) Formulation",
      "short_description": "mRNA/siRNA delivery system assembly",
      "description": "Microfluidic mixing of nucleic acids with ionizable lipids, phospholipids, cholesterol, and PEG-lipids to create delivery nanoparticles. Target size 75\u00b125nm, PDI <0.1, encapsulation >90%. Critical enabling technology for mRNA therapeutics.",
      "stage_id": 24,
      "innovation_potential": "High - enabling nucleic acid therapeutics",
      "complexity_rating": 8
    },
    {
      "technology_id": 47,
      "technology_name": "Microfluidic Mixing",
      "short_description": "Precision nanoparticle assembly",
      "description": "Controlled mixing at microscale enabling reproducible formation of lipid nanoparticles, liposomes, or other nanomedicines. Precise control of mixing parameters (flow rate, ratio, temperature) ensures consistent particle properties.",
      "stage_id": 24,
      "innovation_potential": "High - critical for nanomedicine",
      "complexity_rating": 7
    },
    {
      "technology_id": 48,
      "technology_name": "Automated Visual Inspection (AVI)",
      "short_description": "Machine vision defect detection",
      "description": "High-speed automated inspection using multiple cameras and image processing algorithms to detect particulates, fill volume, container defects, and closure issues. Inspects 100% of units at 400-600 units/minute. Complemented by manual inspection.",
      "stage_id": 33,
      "innovation_potential": "Moderate - AI/ML improvements ongoing",
      "complexity_rating": 6
    },
    {
      "technology_id": 49,
      "technology_name": "Track & Trace Serialization",
      "short_description": "Unit-level unique identifiers",
      "description": "Application of unique 2D barcodes to each unit, bundle, and case per DSCSA/EU FMD requirements. Includes aggregation linking parent-child relationships through packaging hierarchy. Enables supply chain security and anti-counterfeiting.",
      "stage_id": 34,
      "innovation_potential": "Low - regulatory requirement",
      "complexity_rating": 5
    },
    {
      "technology_id": 50,
      "technology_name": "Cold Chain Monitoring",
      "short_description": "Temperature-controlled logistics",
      "description": "Continuous temperature monitoring using data loggers, IoT sensors, and blockchain for unbroken cold chain (2-8\u00b0C or frozen). Qualified shipping containers, mapped shipping lanes, and real-time alerts ensure product integrity for biologics and mRNA vaccines.",
      "stage_id": 35,
      "innovation_potential": "Moderate - digital transformation ongoing",
      "complexity_rating": 6
    },
    {
      "technology_id": 51,
      "technology_name": "Design of Experiments (DoE)",
      "short_description": "Statistical process optimization",
      "description": "Systematic experimentation using factorial or response surface designs to understand relationships between process parameters and quality attributes. Establishes design space and enables science-based manufacturing ranges.",
      "stage_id": 36,
      "innovation_potential": "Low - established QbD tool",
      "complexity_rating": 6
    },
    {
      "technology_id": 52,
      "technology_name": "Process Simulation & Digital Twin",
      "short_description": "Virtual process modeling and optimization",
      "description": "In-silico modeling of manufacturing processes enabling virtual scale-up, process optimization, and troubleshooting. Digital twins integrate real-time data for predictive maintenance and continuous improvement. Accelerates development and reduces physical batches.",
      "stage_id": 37,
      "innovation_potential": "High - Industry 4.0 transformation",
      "complexity_rating": 8
    },
    {
      "technology_id": 53,
      "technology_name": "Near-Infrared Spectroscopy (NIR)",
      "short_description": "Real-time composition analysis",
      "description": "Non-destructive spectroscopic method for real-time monitoring of blend uniformity, moisture content, API concentration, and polymorphic form. Enables continuous release testing and process control without sampling.",
      "stage_id": 39,
      "innovation_potential": "Moderate - PAT workhorse technology",
      "complexity_rating": 6
    },
    {
      "technology_id": 54,
      "technology_name": "Raman Spectroscopy (PAT)",
      "short_description": "Molecular fingerprinting for process control",
      "description": "Vibrational spectroscopy providing molecular-specific information for crystallization monitoring, polymorph identification, and real-time reaction monitoring. More specific than NIR with ability to analyze through glass and in aqueous environments.",
      "stage_id": 39,
      "innovation_potential": "Moderate - expanding PAT applications",
      "complexity_rating": 7
    },
    {
      "technology_id": 55,
      "technology_name": "Focused Beam Reflectance Measurement (FBRM)",
      "short_description": "Real-time particle size monitoring",
      "description": "In-situ probe measuring particle size and count distribution during crystallization, granulation, or dissolution. Enables endpoint determination and process optimization without offline sampling. Critical for controlling crystallization processes.",
      "stage_id": 39,
      "innovation_potential": "Moderate - established PAT for particles",
      "complexity_rating": 6
    },
    {
      "technology_id": 56,
      "technology_name": "Multi-Attribute Method (MAM)",
      "short_description": "Comprehensive protein characterization",
      "description": "High-resolution mass spectrometry-based method simultaneously monitoring 50+ quality attributes (sequence variants, glycosylation, oxidation, deamidation) in single analysis. Replaces multiple conventional assays, accelerates development and lot release.",
      "stage_id": 40,
      "innovation_potential": "High - transforming biologics analytics",
      "complexity_rating": 8
    },
    {
      "technology_id": 57,
      "technology_name": "Capillary Electrophoresis (CE)",
      "short_description": "High-resolution charge variant analysis",
      "description": "Separation based on charge-to-size ratio providing superior resolution of charge variants, aggregates, and fragments versus traditional IEX-HPLC. Essential for characterizing biologics heterogeneity and post-translational modifications.",
      "stage_id": 40,
      "innovation_potential": "Moderate - standard biologics analytical tool",
      "complexity_rating": 6
    }
  ],
  "manufacturing_challenges": [
    {
      "challenge_id": 1,
      "challenge_category": "Safety & Containment",
      "challenge_name": "BSL-2+ Containment Facilities Required",
      "short_description": "Requires specialized biosafety infrastructure for live viral vectors",
      "explanation": "Manufacturing products involving live viral vectors (gene therapies, oncolytic viruses) requires BSL-2+ facilities with negative pressure gradients, advanced waste treatment, specialized PPE, restricted access, and emergency protocols. These facilities prevent escape of viruses that retain ability to replicate or cause infection.",
      "related_capabilities": [
        "BSL-2+ Containment Facilities",
        "Viral Vector Manufacturing",
        "Biosafety & Biosecurity"
      ],
      "primary_stage_id": 13,
      "severity_level": "critical"
    },
    {
      "challenge_id": 2,
      "challenge_category": "Safety & Containment",
      "challenge_name": "High-Potency API (HPAPI) Handling",
      "short_description": "Extreme containment for cytotoxic and highly potent compounds",
      "explanation": "HPAPIs at OEB 3-4 levels (\u22640.1 mg/m\u00b3) can cause cancer, reproductive harm, or immune damage at microscopic doses. Requires barrier isolation, negative pressure, single-use systems, specialized waste handling, comprehensive monitoring, and validated PPE. Significantly increases timelines and costs.",
      "related_capabilities": [
        "High-Potency API Handling",
        "Isolator Technology",
        "Specialized waste handling"
      ],
      "primary_stage_id": 13,
      "severity_level": "critical"
    },
    {
      "challenge_id": 3,
      "challenge_category": "Safety & Containment",
      "challenge_name": "Low Minimum Ignition Energy (MIE) Powder Handling",
      "short_description": "Explosion risk from pharmaceutical powders with low ignition energy",
      "explanation": "Some pharmaceutical powders can be ignited by as little as 3 millijoules of static electricity when airborne, creating explosive dust clouds. Requires inert atmosphere processing (nitrogen), explosion-proof equipment, static elimination, specialized ventilation, and continuous monitoring of oxygen and electrostatic charge.",
      "related_capabilities": [
        "Multi-Step Organic Synthesis",
        "Physical Processing & Drying"
      ],
      "primary_stage_id": 20,
      "severity_level": "major"
    },
    {
      "challenge_id": 4,
      "challenge_category": "Safety & Containment",
      "challenge_name": "Psychoactive Compound Handling",
      "short_description": "Preventing worker exposure to mind-altering compounds",
      "explanation": "Compounds affecting neurotransmitter systems can alter consciousness and impair judgment through inhalation or skin contact. Requires controlled atmosphere processing, sealed systems, comprehensive PPE with respiratory protection, environmental monitoring, and specialized waste destruction to prevent worker impairment and ensure regulatory compliance.",
      "related_capabilities": [
        "High-Potency API Handling",
        "Isolator Technology",
        "Environmental Monitoring (Cleanroom)"
      ],
      "primary_stage_id": 13,
      "severity_level": "major"
    },
    {
      "challenge_id": 5,
      "challenge_category": "Advanced Synthesis",
      "challenge_name": "PROTAC Manufacturing Complexity",
      "short_description": "Multi-component synthesis of large targeted protein degraders",
      "explanation": "PROTACs require assembling three molecular components (target binder, linker, E3 ligase recruiter) with >1000 Da molecular weight. Involves 5-14 synthetic steps with precise linker chemistry, advanced purification for high-MW compounds, and enhanced formulation to overcome poor bioavailability due to size and complexity.",
      "related_capabilities": [
        "PROTAC Synthesis",
        "Advanced Click Chemistry",
        "Multi-Step Organic Synthesis"
      ],
      "primary_stage_id": 13,
      "severity_level": "major"
    },
    {
      "challenge_id": 6,
      "challenge_category": "Advanced Synthesis",
      "challenge_name": "Advanced Peptide Manufacturing",
      "short_description": "Complex peptide synthesis with stereochemistry control",
      "explanation": "Solid-Phase Peptide Synthesis (SPPS) requires building peptides one amino acid at a time with extreme Process Mass Intensity (~13,000). Must control stereochemistry to prevent racemization, ensure sequence fidelity, and prevent aggregation. Requires automated synthesizers, HPLC purification, and specialized analytics.",
      "related_capabilities": [
        "Multi-Step Organic Synthesis",
        "Stereochemistry control",
        "Advanced analytical methods"
      ],
      "primary_stage_id": 13,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 7,
      "challenge_category": "Complex Biologics",
      "challenge_name": "Bispecific Antibody Chain Pairing",
      "short_description": "Controlling correct pairing of different antibody chains",
      "explanation": "Bispecific antibodies require two different heavy chains and potentially different light chains. Without engineering, only ~25% may be correctly paired due to random assembly. Requires knobs-into-holes engineering, charge-based pairing, or common light chain approaches. Challenges include low yield, complex purification, and advanced analytics.",
      "related_capabilities": [
        "Mammalian Cell Culture (CHO/HEK293)",
        "Multi-Step Chromatography Platform",
        "Advanced Analytical Methods"
      ],
      "primary_stage_id": 13,
      "severity_level": "major"
    },
    {
      "challenge_id": 8,
      "challenge_category": "Complex Biologics",
      "challenge_name": "ADC Dual-Stream Manufacturing",
      "short_description": "Coordinating biologics and cytotoxic drug manufacturing",
      "explanation": "ADCs require parallel manufacturing: biologics stream (antibody via cell culture) and chemical stream (cytotoxic payload with OEB4 containment), followed by conjugation with precise Drug-to-Antibody Ratio (DAR 2-4) control. Needs dual containment capabilities, specialized conjugation equipment, and advanced analytics. Regulated as both biologics and chemical drugs.",
      "related_capabilities": [
        "Antibody-Drug Conjugation (ADC)",
        "Site-Specific Conjugation",
        "High-Potency API Handling"
      ],
      "primary_stage_id": 18,
      "severity_level": "critical"
    },
    {
      "challenge_id": 9,
      "challenge_category": "Advanced Therapies",
      "challenge_name": "Viral Vector Production Complexity",
      "short_description": "Complex viral production with stringent purity requirements",
      "explanation": "Beyond containment, viral vectors require specialized cell culture, controlled viral replication, advanced purification separating viral particles from cellular debris, replication-competent virus (RCV) testing, potency assays, and cold chain logistics. Must remove cellular DNA/proteins that could cause immune reactions while maintaining viral infectivity.",
      "related_capabilities": [
        "Viral Vector Manufacturing",
        "BSL-2+ Containment Facilities",
        "Empty/Full Capsid Separation"
      ],
      "primary_stage_id": 13,
      "severity_level": "critical"
    },
    {
      "challenge_id": 10,
      "challenge_category": "Formulation Challenge",
      "challenge_name": "Amorphous Solid Dispersion (ASD) Manufacturing",
      "short_description": "Complex spray drying for poorly soluble compounds",
      "explanation": "Many BCS Class IV drugs require ASD to improve bioavailability. Organic spray drying demands precise control of temperature, airflow, and solvent evaporation. Challenges include polymer selection, scale-up consistency, maintaining amorphous state during storage, and preventing conversion to crystalline forms. Requires solvent recovery and specialized analytical methods.",
      "related_capabilities": [
        "Amorphous Solid Dispersion (ASD) Technology",
        "Spray Drying Technology",
        "Poorly Soluble Compound Formulation"
      ],
      "primary_stage_id": 24,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 11,
      "challenge_category": "Formulation Challenge",
      "challenge_name": "Device & Combination Product Integration",
      "short_description": "Integrating drug with delivery devices",
      "explanation": "Combining pharmaceutical and medical device manufacturing requires dual expertise and regulatory compliance. Challenges include device integration, aseptic assembly of sterile drug-device combinations, multi-component supply chain management, and meeting both drug and device regulations. Often requires partnerships with specialized device manufacturers.",
      "related_capabilities": [
        "Auto-Injector Device Integration",
        "Pre-Filled Syringe Manufacturing",
        "Aseptic Fill-Finish (Biologics)"
      ],
      "primary_stage_id": 32,
      "severity_level": "major"
    },
    {
      "challenge_id": 12,
      "challenge_category": "Formulation Challenge",
      "challenge_name": "Tissue-Specific Targeting Formulation",
      "short_description": "Designing formulations for organ/tissue accumulation",
      "explanation": "Achieving drug accumulation in specific organs (lungs, brain, tumors) while avoiding others requires particle size engineering, lipid-based systems, targeted delivery molecules, or controlled release. Different tissues have unique barriers (e.g., blood-brain barrier). Needs specialized particle processing, advanced formulation, tissue-specific testing, and stability optimization.",
      "related_capabilities": [
        "Poorly Soluble Compound Formulation",
        "Controlled Release Technology",
        "Advanced formulation techniques"
      ],
      "primary_stage_id": 24,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 13,
      "challenge_category": "Formulation Challenge",
      "challenge_name": "Lipophilic Membrane-Targeted Formulation",
      "short_description": "Balancing lipophilicity for membrane protein targeting",
      "explanation": "Drugs targeting membrane proteins need lipophilic character to reach membrane environment while maintaining sufficient aqueous solubility for administration. Challenges include achieving lipophilic-hydrophilic balance, ensuring membrane partitioning, preventing degradation, and maintaining consistency at scale. Requires specialized mixing, advanced analytics, and environmental controls.",
      "related_capabilities": [
        "Poorly Soluble Compound Formulation",
        "Biologics Formulation Development"
      ],
      "primary_stage_id": 24,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 14,
      "challenge_category": "Distribution Challenge",
      "challenge_name": "Cold Chain Logistics",
      "short_description": "Temperature-controlled supply chain from manufacturing to patient",
      "explanation": "Temperature-sensitive biologics and complex molecules lose potency or become dangerous outside specified ranges. Requires validated cold storage, specialized insulated packaging, refrigerated transportation, real-time monitoring, and contingency planning. Costs 2-5x more than ambient distribution with global infrastructure challenges.",
      "related_capabilities": [
        "Cold Chain Management",
        "Cryogenic Storage & Handling"
      ],
      "primary_stage_id": 35,
      "severity_level": "critical"
    },
    {
      "challenge_id": 15,
      "challenge_category": "Purification Challenge",
      "challenge_name": "High-Selectivity Synthesis Requirements",
      "short_description": "Achieving >300-fold enzyme selectivity",
      "explanation": "Creating molecules with >300-fold selectivity for target enzyme over related enzymes requires stereochemical precision and minimal impurities. Even trace amounts of wrong isomers or related compounds compromise selectivity. Demands rigorous purification, multi-enzyme selectivity testing, process validation, and stringent raw material control.",
      "related_capabilities": [
        "Asymmetric Synthesis",
        "Ultra-High Purity Purification",
        "Advanced Analytical Methods"
      ],
      "primary_stage_id": 17,
      "severity_level": "major"
    },
    {
      "challenge_id": 16,
      "challenge_category": "Synthesis Challenge",
      "challenge_name": "Covalent Inhibitor Stability Control",
      "short_description": "Balancing stability and therapeutic reactivity",
      "explanation": "Covalent inhibitors must be stable during manufacturing/storage but reactive enough for therapeutic effect. Walking this tightrope requires controlled reactivity, preventing premature reactions with equipment/containers, preserving target selectivity, and extensive stability-reactivity testing. Needs inert processing, specialized storage, and continuous monitoring.",
      "related_capabilities": [
        "Multi-Step Organic Synthesis",
        "Transition Metal Catalysis",
        "Process validation"
      ],
      "primary_stage_id": 13,
      "severity_level": "major"
    },
    {
      "challenge_id": 17,
      "challenge_category": "Purification Challenge",
      "challenge_name": "Endotoxin-Free Manufacturing",
      "short_description": "Complete endotoxin elimination for immunomodulators",
      "explanation": "Immunomodulatory compounds amplify immune responses to even trace endotoxins, causing fever, inflammation, or life-threatening reactions. Requires endotoxin-free materials/water, specialized manufacturing environment, depyrogenation processes, and extensive testing. Challenges include maintaining endotoxin-free water systems, equipment cleaning, environmental monitoring, and supply chain control.",
      "related_capabilities": [
        "Viral Clearance & Safety",
        "Environmental Monitoring (Cleanroom)",
        "cGMP"
      ],
      "primary_stage_id": 19,
      "severity_level": "critical"
    },
    {
      "challenge_id": 18,
      "challenge_category": "Complex Biologics",
      "challenge_name": "Complex Biologics Manufacturing",
      "short_description": "Specialized production of fusion proteins and receptor modulators",
      "explanation": "Beyond standard mAbs, complex biologics like fusion proteins and receptor modulators have unique structural requirements affecting production, purification, and characterization. Require specialized expression systems, advanced purification preserving complex structures, structure-function analysis, and bioactivity testing. Extensive process development and novel analytical methods needed.",
      "related_capabilities": [
        "Mammalian Cell Culture (CHO/HEK293)",
        "Multi-Step Chromatography Platform",
        "Advanced Analytical Methods"
      ],
      "primary_stage_id": 13,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 19,
      "challenge_category": "Process Technology",
      "challenge_name": "Continuous Manufacturing Implementation",
      "short_description": "Transitioning from batch to continuous processing",
      "explanation": "Implementing continuous manufacturing (e.g., Twin Screw Granulation) requires fundamentally different equipment, process controls, and operations versus batch. Challenges include major capital investment in new facilities, adapting to evolving regulatory guidelines, complete operational retraining, and developing real-time quality assurance methods. Benefits include reduced costs and improved consistency when successful.",
      "related_capabilities": [
        "Continuous Manufacturing (Pharma)",
        "Twin Screw Granulation (TSG)",
        "Process Analytical Technology (PAT)"
      ],
      "primary_stage_id": 29,
      "severity_level": "major"
    },
    {
      "challenge_id": 20,
      "challenge_category": "Supply Chain Strategy",
      "challenge_name": "Outsourced/Hybrid Supply Chain Management",
      "short_description": "Coordinating multiple specialized contract manufacturers",
      "explanation": "Advanced products often require networks of specialized CDMOs (Vetter, Rentschler, Lonza) for different steps. Management challenges include timeline coordination across partners, technical transfer while maintaining quality, quality oversight, supply chain visibility, and risk management for disruptions. Requires standardized processes, robust communication, quality agreements, and contingency planning.",
      "related_capabilities": [
        "Supply Chain Risk Management",
        "Scale-Up & Technology Transfer",
        "Regulatory CMC Submissions"
      ],
      "primary_stage_id": 38,
      "severity_level": "major"
    },
    {
      "challenge_id": 21,
      "challenge_category": "Purification Challenge",
      "challenge_name": "Empty/Full AAV Capsid Separation",
      "short_description": "Separating functional from non-functional viral particles",
      "explanation": "Critical quality issue for AAV gene therapies requiring separation of full (therapeutic) capsids containing genetic payload from empty capsids lacking DNA. Traditional ultracentrifugation difficult to scale; advanced chromatography methods needed. Empty capsids can trigger immune responses without therapeutic benefit, making this separation essential for product quality and safety.",
      "related_capabilities": [
        "Empty/Full Capsid Separation",
        "Viral Vector Manufacturing",
        "Advanced chromatography"
      ],
      "primary_stage_id": 17,
      "severity_level": "critical"
    },
    {
      "challenge_id": 22,
      "challenge_category": "Advanced Therapies",
      "challenge_name": "Autologous Cell Therapy Chain of Identity",
      "short_description": "Maintaining patient-cell identity through manufacturing",
      "explanation": "Vein-to-vein manufacturing for autologous CAR-T requires rigorous tracking from patient leukapheresis through isolation, genetic modification, expansion (7-14 days), and re-infusion. Current timelines 3-5 weeks. Any mix-up could be fatal. Requires sophisticated tracking systems, quality controls, and contamination prevention with next-gen 24-hour processes under development.",
      "related_capabilities": [
        "Autologous Cell Processing",
        "Vein-to-Vein Logistics",
        "Ex-Vivo Cell Expansion"
      ],
      "primary_stage_id": 28,
      "severity_level": "critical"
    },
    {
      "challenge_id": 23,
      "challenge_category": "Advanced Therapies",
      "challenge_name": "mRNA Stability & Ultra-Cold Storage",
      "short_description": "Preventing mRNA degradation during manufacturing and distribution",
      "explanation": "mRNA rapidly degrades without protection. Requires careful formulation in lipid nanoparticles, ultra-cold storage (-70\u00b0C), and validated cold chain logistics throughout manufacturing and distribution. Challenges include maintaining LNP integrity, preventing RNA hydrolysis, ensuring encapsulation efficiency remains high, and global distribution to areas with limited ultra-cold infrastructure.",
      "related_capabilities": [
        "Lipid Nanoparticle (LNP) Formulation",
        "Cryogenic Storage & Handling",
        "Cold Chain Management"
      ],
      "primary_stage_id": 24,
      "severity_level": "critical"
    },
    {
      "challenge_id": 24,
      "challenge_category": "Quality Attribute",
      "challenge_name": "Sub-Visible Particle Control",
      "short_description": "Managing protein aggregation in biologics",
      "explanation": "Critical quality attribute for biologics safety and efficacy. Protein aggregates (0.1-100 \u03bcm) not visible to naked eye can trigger immune responses or reduce potency. Requires optimized formulation (pH, excipients, ionic strength), gentle processing to minimize shear stress, advanced analytical detection (light obscuration, flow imaging), and process controls throughout manufacturing.",
      "related_capabilities": [
        "Biologics Formulation Development",
        "Process Analytical Technology (PAT)",
        "Advanced Analytical Methods"
      ],
      "primary_stage_id": 21,
      "severity_level": "major"
    },
    {
      "challenge_id": 25,
      "challenge_category": "Process Intensification",
      "challenge_name": "High Titer Biologics Production",
      "short_description": "Achieving antibody titers >10 g/L",
      "explanation": "Process intensification to achieve >10 g/L antibody titers requires optimized media formulation, advanced feeding strategies, extended culture durations (14+ days), cell line engineering for high productivity, and large-scale bioreactor operation (2,000-20,000L). Benefits include reduced manufacturing footprint and cost per dose, but increases complexity of upstream processing.",
      "related_capabilities": [
        "Fed-Batch Culture Optimization",
        "Perfusion Culture Technology",
        "Cell Line Development & Engineering"
      ],
      "primary_stage_id": 14,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 26,
      "challenge_category": "Regulatory Challenge",
      "challenge_name": "Process Validation for Continuous Systems",
      "short_description": "Validating continuous manufacturing per ICH Q13",
      "explanation": "Continuous manufacturing requires new validation paradigms versus traditional batch approaches. Must demonstrate residence time distribution modeling, material traceability through integrated systems, real-time release testing strategies, and process control throughout continuous operation. ICH Q13 provides framework but implementation requires extensive development and regulatory interaction.",
      "related_capabilities": [
        "Continuous Manufacturing (Pharma)",
        "Quality by Design (QbD)",
        "Real-Time Release Testing (RTRT)"
      ],
      "primary_stage_id": 12,
      "severity_level": "major"
    },
    {
      "challenge_id": 27,
      "challenge_category": "Analytical Challenge",
      "challenge_name": "Multi-Attribute Method (MAM) Implementation",
      "short_description": "Comprehensive biologics characterization in single assay",
      "explanation": "MAM uses high-resolution mass spectrometry to simultaneously monitor 50+ quality attributes (sequence variants, glycosylation, oxidation, deamidation) replacing multiple conventional assays. Accelerates development and lot release but requires significant analytical expertise, method development/validation, data management systems, and regulatory acceptance for new analytical paradigm.",
      "related_capabilities": [
        "Advanced Analytical Methods",
        "Mass Spectrometry (Protein Characterization)"
      ],
      "primary_stage_id": 40,
      "severity_level": "moderate"
    },
    {
      "challenge_id": 28,
      "challenge_category": "Contamination Control",
      "challenge_name": "Sterility Assurance for Advanced Therapies",
      "short_description": "Preventing contamination in complex cell therapy manufacturing",
      "explanation": "Advanced therapies require extended ex-vivo culture periods (7-14 days) with multiple open processing steps for cell manipulation. Unlike traditional aseptic processing, cannot terminal sterilize. Requires robust aseptic technique, environmental monitoring, validated single-use systems, operator training, and process controls to prevent bacterial/fungal contamination while maintaining cell viability.",
      "related_capabilities": [
        "Autologous Cell Processing",
        "Environmental Monitoring (Cleanroom)",
        "Aseptic Processing"
      ],
      "primary_stage_id": 28,
      "severity_level": "critical"
    },
    {
      "challenge_id": 29,
      "challenge_category": "Purification Challenge",
      "challenge_name": "Oligonucleotide Purification to High Purity",
      "short_description": "Achieving >85% main peak purity for therapeutic oligos",
      "explanation": "Oligonucleotide synthesis generates multiple truncated sequences (n-1, n-2, etc.) and modified species requiring separation. Must achieve >85-90% main peak purity for mRNA or >95% for antisense oligos. Requires HPLC and ion-exchange chromatography with careful method development, plus DNase treatment for mRNA to remove template DNA. Challenging due to similar properties of impurities.",
      "related_capabilities": [
        "Nucleic Acid Manufacturing",
        "Multi-Step Chromatography Platform",
        "Advanced Analytical Methods"
      ],
      "primary_stage_id": 17,
      "severity_level": "moderate"
    }
  ],
  "llm_settings": [],
  "template_stages": [
    {
      "template_id": 2,
      "stage_id": 15,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Bacterial Strain Development",
        "Master/Working Cell Bank Creation"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Bacterial Fermentation",
        "Anaerobic/Aerobic Culture"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 16,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Centrifugation",
        "Cell Harvest"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 7,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Cryoprotectant Selection",
        "Buffer Optimization"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 31,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Viability Preservation",
        "Freeze-Drying"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 26,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Blending",
        "Encapsulation"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 21,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Cell Viability Assays",
        "Strain Identity Testing"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 22,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Controlled Storage",
        "Long-term Stability Programs"
      ]
    },
    {
      "template_id": 2,
      "stage_id": 42,
      "stage_order": 9,
      "is_required": true,
      "base_capabilities": [
        "BSL-2 Containment",
        "Quality Systems"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "In Vitro Transcription (IVT)",
        "Plasmid DNA Production"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 17,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "mRNA Purification",
        "Oligo Purification"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 24,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Lipid Nanoparticle (LNP) Formulation",
        "Microfluidics Mixing"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 7,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Buffer Exchange",
        "Concentration"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 27,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filtration",
        "Aseptic Environment Control"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 30,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Vial Filling",
        "Aseptic Technique"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 21,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "RNA Integrity",
        "Particle Size Analysis",
        "Encapsulation Efficiency"
      ]
    },
    {
      "template_id": 3,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Ultra-Cold Storage (-70C)",
        "Cryogenic Shipping"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 28,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Apheresis Collection",
        "NK Cell Isolation"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 15,
      "stage_order": 2,
      "is_required": false,
      "base_capabilities": [
        "Allogeneic Master Cell Banking (for off-the-shelf)",
        "Donor Screening"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 13,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Gene Transfer (e.g., mRNA electroporation)",
        "CAR Construct Engineering"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 4,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "NK Cell Expansion",
        "Bioreactor Culture"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 5,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Cell Harvest",
        "Washing & Concentration"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 7,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Cryopreservation Media Formulation",
        "Final Product Formulation"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 30,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Cryobag Filling",
        "Aseptic Transfer"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 32,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Controlled-Rate Freezing",
        "Cryogenic Storage"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 21,
      "stage_order": 9,
      "is_required": true,
      "base_capabilities": [
        "Potency Assays",
        "Flow Cytometry",
        "Sterility Testing"
      ]
    },
    {
      "template_id": 4,
      "stage_id": 35,
      "stage_order": 10,
      "is_required": true,
      "base_capabilities": [
        "Cryogenic Logistics",
        "Chain of Identity Management"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 28,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Leukapheresis",
        "T-Cell Isolation & Activation"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Viral Transduction (Lentivirus/Retrovirus)",
        "Gene Transfer"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 4,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "T-Cell Expansion",
        "Closed System Bioreactor Operation"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 5,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Cell Harvest",
        "Washing & Formulation"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 30,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Final Product Formulation",
        "Cryobag Filling"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 32,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Controlled-Rate Freezing",
        "Cryogenic Storage"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 21,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Potency Assay",
        "Transduction Efficiency",
        "Sterility"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Cryogenic Logistics",
        "Chain of Custody",
        "Patient Scheduling"
      ]
    },
    {
      "template_id": 5,
      "stage_id": 42,
      "stage_order": 9,
      "is_required": true,
      "base_capabilities": [
        "Aseptic Processing",
        "Quality Systems"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 15,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Producer/Packaging Cell Line Creation",
        "Cell Banking"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Plasmid Production",
        "Cell Culture & Transfection/Infection"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 16,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Cell Lysis",
        "Depth Filtration",
        "Microfiltration"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 17,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Affinity Chromatography",
        "Ion-Exchange Chromatography",
        "Empty/Full Capsid Separation"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 19,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Adventitious Agent Testing",
        "Impurity Profiling"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 7,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Buffer Formulation",
        "Excipient Selection"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 27,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filtration",
        "Aseptic Filling Operations"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 30,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Vial Filling",
        "Container Closure"
      ]
    },
    {
      "template_id": 6,
      "stage_id": 35,
      "stage_order": 9,
      "is_required": true,
      "base_capabilities": [
        "Frozen Storage & Shipping",
        "Temperature Control"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Complex Organic Synthesis",
        "API Production"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 17,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Impurity Profiling",
        "High-Performance Liquid Chromatography (HPLC)"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 20,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Crystallization",
        "Drying",
        "Milling"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 24,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Polymorph Screening",
        "Amorphous Solid Dispersion (ASD)"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 7,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Excipient Compatibility",
        "Bioavailability Enhancement"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 26,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Blending",
        "Tablet Compression",
        "Capsule Filling"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 21,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Analytical Method Development",
        "Release Specification Testing"
      ]
    },
    {
      "template_id": 7,
      "stage_id": 34,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Blister/Bottle Packaging",
        "Track and Trace"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 15,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "CHO Cell Line Engineering",
        "Clonal Selection",
        "Cell Banking"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Upstream Processing",
        "Fed-Batch/Perfusion Bioreactors"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 16,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Centrifugation",
        "Depth Filtration"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 17,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Protein A Chromatography",
        "Ion-Exchange Chromatography",
        "Viral Filtration"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 19,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Low pH Viral Inactivation",
        "Viral Filtration",
        "Adventitious Agent Testing"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 7,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Buffer Screening",
        "Excipient Selection",
        "High Concentration Formulation"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 27,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filtration",
        "Cleanroom Operations"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 30,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Vial/Syringe Filling",
        "Stopper/Plunger Placement"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 31,
      "stage_order": 9,
      "is_required": false,
      "base_capabilities": [
        "Freeze-Drying",
        "Product Stability Enhancement"
      ]
    },
    {
      "template_id": 8,
      "stage_id": 35,
      "stage_order": 10,
      "is_required": true,
      "base_capabilities": [
        "Refrigerated Storage (2-8C)",
        "Qualified Shippers"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Solid-Phase Oligonucleotide Synthesis",
        "Amidite Chemistry"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 16,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Cleavage & Deprotection",
        "Crude Product Isolation"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 17,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Reverse Phase HPLC",
        "Ion-Exchange HPLC"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 24,
      "stage_order": 4,
      "is_required": false,
      "base_capabilities": [
        "LNP Formulation",
        "GalNAc Conjugation"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 7,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Buffer Exchange",
        "Salt Removal"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 27,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filtration",
        "Aseptic Filling"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 31,
      "stage_order": 7,
      "is_required": false,
      "base_capabilities": [
        "Freeze-Drying"
      ]
    },
    {
      "template_id": 9,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Refrigerated or Frozen Storage",
        "Temperature-Controlled Shipping"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Multi-Component Synthesis",
        "Linker Chemistry",
        "API Production"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 17,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Preparative HPLC",
        "Impurity Isolation and Characterization"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 20,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Drying",
        "Milling"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 24,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Amorphous Solid Dispersion (ASD)",
        "Solubility Enhancement Techniques"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 7,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Excipient Selection",
        "Oral Formulation Design"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 26,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Tablet Compression",
        "Capsule Filling"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 21,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Complex Analytical Testing",
        "Stability Testing"
      ]
    },
    {
      "template_id": 10,
      "stage_id": 34,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Packaging",
        "Track and Trace"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Solid-Phase Peptide Synthesis (SPPS)",
        "Solution Phase Synthesis"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 17,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Reverse Phase HPLC Purification",
        "Purity Analysis"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 31,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Freeze-Drying",
        "API Isolation"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 7,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Sterile Liquid Formulation",
        "Stability Optimization"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 27,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filtration",
        "Aseptic Filling"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 30,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Vial Filling",
        "Cartridge Filling"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 32,
      "stage_order": 7,
      "is_required": false,
      "base_capabilities": [
        "Auto-injector Assembly",
        "Pen Device Integration"
      ]
    },
    {
      "template_id": 11,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Refrigerated Storage and Shipping"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 36,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "User Needs Definition",
        "Software Requirements Specification",
        "Design Controls"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 37,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Software Architecture Design",
        "Coding and Unit Testing",
        "Agile/Waterfall Development"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 33,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Software Verification & Validation (V&V)",
        "Integration Testing",
        "Usability Testing"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 38,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Cybersecurity Management",
        "Third-Party Software (SOUP) Management"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 21,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Final Release Testing",
        "Deployment to Production Environment"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 43,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "SaMD Regulatory Documentation (e.g., FDA 510(k))",
        "CE Marking"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 44,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Quality Management System (QMS) Audits",
        "Post-Market Surveillance",
        "Complaint Handling"
      ]
    },
    {
      "template_id": 12,
      "stage_id": 45,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Compliance with IEC 62304",
        "Compliance with ISO 13485",
        "HIPAA/GDPR Compliance"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Radioisotope Production (Cyclotron/Generator)",
        "Ligand/Precursor Synthesis"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 18,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Automated Radiosynthesis",
        "Radiolabeling"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 17,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Rapid HPLC Purification",
        "Radiochemical Purity Assessment"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 27,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filtration",
        "Hot Cell Operations"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 21,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Rapid Sterility/Endotoxin Testing",
        "Half-life Confirmation",
        "Dose Calibration"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 30,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Dispensing into Shielded Vials",
        "Aseptic Filling"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 35,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Just-in-Time Logistics",
        "Radioactive Material Transport"
      ]
    },
    {
      "template_id": 13,
      "stage_id": 42,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Radiation Safety",
        "Specialized Facility Compliance"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 15,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Expression System Selection (Mammalian/Microbial)",
        "Cell Banking"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Cell Culture / Fermentation",
        "Bioreactor Operation"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 16,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Cell Harvest / Lysis",
        "Filtration"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 17,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Multi-column Purification",
        "Refolding (if applicable)"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 19,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Impurity Profiling",
        "Viral Clearance Studies"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 7,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Protein Stabilization",
        "Buffer Selection"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 27,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Sterile Manufacturing",
        "Aseptic Filling"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 30,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Vial/Syringe Filling"
      ]
    },
    {
      "template_id": 14,
      "stage_id": 35,
      "stage_order": 9,
      "is_required": true,
      "base_capabilities": [
        "Refrigerated/Frozen Logistics"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 13,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Chemical Synthesis",
        "API Production",
        "Crystallization"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 20,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Drying",
        "Milling",
        "Particle Size Control"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 24,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Salt Selection",
        "Polymorph Control"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 7,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Excipient Selection",
        "Tablet/Capsule Formulation"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 26,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Blending",
        "Granulation",
        "Tablet Compression",
        "Capsule Filling"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 21,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Analytical Testing",
        "Dissolution Testing",
        "Release Testing"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 34,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Packaging",
        "Serialization",
        "Track and Trace"
      ]
    },
    {
      "template_id": 15,
      "stage_id": 29,
      "stage_order": 8,
      "is_required": false,
      "base_capabilities": [
        "Continuous Processing",
        "Process Analytical Technology (PAT)"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 28,
      "stage_order": 1,
      "is_required": false,
      "base_capabilities": [
        "Autologous Cell Sourcing",
        "Patient Material Handling"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 15,
      "stage_order": 2,
      "is_required": false,
      "base_capabilities": [
        "Allogeneic Master Cell Bank Creation",
        "Donor Qualification"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 4,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Stem Cell Expansion",
        "Cell Differentiation Protocols",
        "Bioreactor Culture"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 5,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Cell Harvest",
        "Washing & Concentration"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 7,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Cryopreservation Media Development",
        "Final Product Formulation"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 30,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Aseptic Filling into Vials/Bags"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 32,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Controlled-Rate Freezing",
        "Cryogenic Storage"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 21,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Cell Viability",
        "Identity Markers",
        "Potency Assays"
      ]
    },
    {
      "template_id": 16,
      "stage_id": 35,
      "stage_order": 9,
      "is_required": true,
      "base_capabilities": [
        "Cryogenic Logistics",
        "Chain of Identity"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 15,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Advanced Protein Engineering",
        "Stable Cell Line Generation",
        "Chain Pairing Control"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Controlled Expression Culture",
        "Bioreactor Operation"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 16,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Cell Harvest",
        "Filtration"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 17,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Multi-step Purification",
        "Mispairing/Aggregate Removal"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 40,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Mass Spectrometry",
        "Product Variant Characterization"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 7,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Stability Enhancement",
        "High Concentration Formulation"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 27,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filling",
        "Cleanroom Management"
      ]
    },
    {
      "template_id": 17,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Refrigerated Logistics"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 28,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Apheresis Collection",
        "T-Cell Isolation"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "TCR Gene Transfer",
        "Viral Transduction"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 4,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "T-Cell Expansion",
        "Bioreactor Culture"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 5,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Cell Harvest",
        "Washing and Formulation"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 30,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Cryobag Filling"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 32,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Controlled-Rate Freezing"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 21,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Potency Assay",
        "TCR Expression Analysis",
        "Sterility Testing"
      ]
    },
    {
      "template_id": 18,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Cryogenic Logistics",
        "Chain of Identity"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 15,
      "stage_order": 1,
      "is_required": true,
      "base_capabilities": [
        "Multi-Chain Protein Engineering",
        "Clonal Selection for Correct Assembly"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 13,
      "stage_order": 2,
      "is_required": true,
      "base_capabilities": [
        "Complex Bioreactor Process Control",
        "Upstream Production"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 16,
      "stage_order": 3,
      "is_required": true,
      "base_capabilities": [
        "Harvesting",
        "Clarification"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 17,
      "stage_order": 4,
      "is_required": true,
      "base_capabilities": [
        "Sophisticated Multi-Step Purification",
        "Product-Related Impurity Removal"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 40,
      "stage_order": 5,
      "is_required": true,
      "base_capabilities": [
        "Extensive Characterization",
        "Binding Assays for all Targets"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 7,
      "stage_order": 6,
      "is_required": true,
      "base_capabilities": [
        "Aggregation Prevention",
        "Long-Term Stability Formulation"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 27,
      "stage_order": 7,
      "is_required": true,
      "base_capabilities": [
        "Sterile Filling Operations"
      ]
    },
    {
      "template_id": 19,
      "stage_id": 35,
      "stage_order": 8,
      "is_required": true,
      "base_capabilities": [
        "Refrigerated Logistics"
      ]
    }
  ],
  "product_to_challenge": [],
  "product_to_technology": [],
  "product_supply_chain": [],
  "modality_requirements": [],
  "product_requirements": [],
  "entity_capabilities": [],
  "product_process_overrides": [],
  "product_timelines": [],
  "product_regulatory_filings": [],
  "product_manufacturing_suppliers": [
    {
      "supplier_id": 16,
      "product_id": 9,
      "supply_type": "DS",
      "supplier_name": "Cambrex",
      "site_name": "N/A",
      "site_location": null,
      "role": "Primary",
      "status": "qualified",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 17,
      "product_id": 9,
      "supply_type": "DS",
      "supplier_name": "Alphora",
      "site_name": "N/A",
      "site_location": null,
      "role": "Backup",
      "status": "qualified",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 18,
      "product_id": 9,
      "supply_type": "DP",
      "supplier_name": "Hovione",
      "site_name": "Portugal",
      "site_location": null,
      "role": "Launch",
      "status": "launch_ready",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 19,
      "product_id": 9,
      "supply_type": "DP",
      "supplier_name": "ING",
      "site_name": "Ingelheim",
      "site_location": null,
      "role": "Launch",
      "status": "launch_ready",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 20,
      "product_id": 10,
      "supply_type": "DS",
      "supplier_name": "ING",
      "site_name": "Ingelheim",
      "site_location": null,
      "role": "Primary",
      "status": "qualified",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 21,
      "product_id": 10,
      "supply_type": "DP",
      "supplier_name": "ING_SoL",
      "site_name": "Ingelheim",
      "site_location": null,
      "role": "Launch",
      "status": "qualified",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 22,
      "product_id": 11,
      "supply_type": "DS",
      "supplier_name": "PPG",
      "site_name": "N/A",
      "site_location": null,
      "role": "Primary",
      "status": "halted",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 23,
      "product_id": 11,
      "supply_type": "DP",
      "supplier_name": "Thermo Fisher",
      "site_name": "N/A",
      "site_location": null,
      "role": "Manufacturing",
      "status": "ongoing",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 24,
      "product_id": 11,
      "supply_type": "DP",
      "supplier_name": "Nemera",
      "site_name": "N/A",
      "site_location": null,
      "role": "Device",
      "status": "ramp-up",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 25,
      "product_id": 12,
      "supply_type": "DS",
      "supplier_name": "ING",
      "site_name": "Ingelheim",
      "site_location": null,
      "role": "Primary",
      "status": "transfer ongoing",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    },
    {
      "supplier_id": 26,
      "product_id": 12,
      "supply_type": "DP",
      "supplier_name": "ING_SoL",
      "site_name": "Ingelheim",
      "site_location": null,
      "role": "Primary",
      "status": "transfer ongoing",
      "technology": null,
      "start_date": null,
      "qualification_date": null,
      "notes": null,
      "created_at": "2025-09-24T17:19:30.836942+00:00",
      "updated_at": null
    }
  ]
}